Confidential Page 1 of 114 
1. TITLE PAGE
BEMPEDOIC ACID (ETC-1002)  
1002 -039 
A RANDOMIZED, DOUBLE -BLIND, PARALLEL  GROUP, 
MULTICENTER STUDY TO  EVALUATE THE EFFICAC Y AND SAFETY 
OF BEMPEDOIC ACID (E TC-1002) 180  MG QD WHEN ADDED TO 
PROPROTEIN CONVERTAS E SUBTILISIN/KEXIN TYPE  9 
(PCSK9 )-INHIBITOR  THERAPY  
Study Phase:  2 
IND Number:  106,[ADDRESS_344646] Number:  n/a 
Indication:  Treatment of hyperlipi[INVESTIGATOR_282596]: Approximately 20-30 sites located in North America 
Sponsor:  Esperion Therapeutics, Inc. 
[ADDRESS_344647] Ann Arbor, MI [ZIP_CODE] Phone: [PHONE_5873] Fax: [PHONE_5874] 
Sponsor Contact: 
[CONTACT_25290]:  
V
ersi on Date  
Original Protocol  22 November 2016  
Prot ocol Amendment 1: [ADDRESS_344648] NEED TO KNOW , WITH THE OBLIGATION NOT TO FURTHER
DISSEMINATE THIS INFORMATION . THESE RESTRICTIONS ON  DISCLOS URE WILL APPLY EQUALLY TO ALL FUTURE ORAL OR WRITTEN
INFORMATION , SUPPLIED TO YOU BY [CONTACT_76745] , INC., WHICH IS DESIGNATED AS ‚ÄúPRIVILEGED ‚Äù OR ‚ÄúCONFIDENTIAL .‚Äù 
NCT number: [STUDY_ID_REMOVED]
This NCT number has been applied to the document
for purposes of posting on clinicaltrials.gov

Bempedoic Acid  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039 Amendment 1, 05 March 2017 
Confidential Page 2 of 114 2. SYNOPSIS
Name [CONTACT_790]:  Esperion Therapeutics, Inc.  
Name [CONTACT_791]:  Bempedoic acid (ETC-1002) film- coated tablets  
Name [CONTACT_3261]:  Bempedoic acid  
Title of Study: 
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety o f 
Bempedoic Acid (ETC -1002) 180 mg QD when added to PCSK9- Inhibitor Therapy   
Study Number:  1002-039 
Phase of Development:  2 
Clinical Sites:  Approximately 20 sites located in North America 
Objectives: 
Primary: 
‚Ä¢To assess the 2-month efficacy of bempedoic acid 180 mg/day vs placebo in the reduction of low -
density lipoprotein cholesterol (LDL-C) in patients on proprotein convertase subtilisin/kexin
type 9 inhibitor (PCSK9 i) therapy
Secondary: 
‚Ä¢To assess the 1-month efficacy of bempedoic acid 180 mg/day vs placebo in the reduction of
LDL -C in patients on PCSK9i therapy
‚Ä¢To evaluate the effect of bempedoic acid 180 mg/day vs placebo on apolipoprotein B ( ApoB),
non-high-density lipoprot ein cholesterol (non- HDL -C), total cholesterol (TC), and high-
sensitivity C -reactive protein (hs- CRP) after 1 and 2 months of treatment
‚Ä¢To evaluate the safety and tolerability of bempedoic acid 180 mg/day c ompared to placebo in
patients on PCSK9i therapy
Exploratory: 

%HPSHGRLF$FLG (VSHUL RQ7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO  $PHQGPHQW0DUFK
&RQILGHQWLDO 3DJHRI0HWKRGRORJ\
678'<'(6,*1

7KLVLVD3KDVHUDQGRPL]HGGRXEOHEOLQGSODFHERFRQWUROOHG SDUDOOHOJURXSPXOWLFHQWHUVWXG\WKDWZLOO
EHFRQGXFWHGDWDSSUR[LPDWHO\FOLQLFDOVLWHVLQ1RUWK$PHULF D6FUHHQLQJ9LVLW6ZLOORFFXU
DSSUR[LPDWHO\PRQWKVSULRUW RUDQGRPL]DWLRQ$IWHUSURYLGL QJLQIRUPHGFRQVHQWDW9LVLW6SDWLHQWV
ZLOOVWRSDOOEDFNJURXQGOLSLGORZHULQJWKHUDS\DQGOLSLGPRGLI \LQJQXWULWLRQDOVXSSOHPHQWVLI
DSSOLFDEOH$OOSDWLHQWVZLOOUHWXUQWRWKHFOLQLFRQ0RQWK 9LVLW6'XULQJWKLVYLVLWSDWLHQWVZLWKDQ
/'/&YDOXH¬ïPJG/YLDFHQWUDORUORFDOODEDQGWULJO\FHU LGHVPJG/ YLDFHQWUDORUORFDOODE
ZLOOLQLWLDWH3&6.EDFNJURXQGWKHUDS\5HSDWKDPJRQFHPRQ WKO\>40@6LWHVWKDWGRQRWXVHD
ORFDOODEPD\QHHGWREULQJSDWLHQWVEDFNIRUDQRWKHUYLVLWWR DGPLQLVWHU3&6.EDFNJURXQGWKHUDS\DVD
TXDOLI\LQJ/'/&YDOXHLVUHTXLUHGSULRUWRLQLWLDWLQJWKHPR QWK3&6.LUXQLQSHULRG1RRWKHU
EDFNJURXQGOLSLGPRGLI\LQJWKHUDS\ H[FHSWVWXG\SURYLGHG3&6.L ZLOOEHSHUPLWWHGGXULQJWKHWULDO
$IWHUPRQWKDWOHDVW¬ìGD\V SDWLHQWVZLOOUHWXUQWRW KHFOLQLFIRU0RQWK9LVLW6IROORZHGE\
0RQWK9LVLW6¬ìGD\VODWHU'XULQJWKHVHYLVLWV5H SDWKDZLOOEHDGPLQLVWHUHGODEVZLOOEH
FROOHFWHGDQGVDIHW\DVVHVVHG$W9LVLW6/'/&ZLOOEHFKH FNHGDVHFRQGWLPHSULRUWRUDQGRPL]DWLRQ
3DWLHQWVZLWKDQ/'/&¬ïPJG/ YLDFHQWUDOODERQO\DWWKLV YLVLWZLOOTXDOLI\IRUUDQGRPL]DWLRQ
3DWLHQWVZLWK/'/&PJG/DW 9LVLW6ZLOOEHVFUHHQIDLOHG DQGQRIXUWKHU3&6.LWKHUDS\ZLOOEH
DGPLQLVWHUHG'D\VKRXOGRFFXUGD\V¬ìGD\VDIWHU9LVLW 6RQFH/'/&HOLJLELOLW\LVHVWDEOLVKHG
2Q'D\TXDOLILHGSDWLHQWVZLOOEHUDQGRPL]HGWREHPSHGRL FDFLGPJGD\Q RUPDWFKLQJ
SODFHERQ 5DQGRPL]HGSDWLHQWVZLOOUHWXUQIRUFOLQLFY LVLWVDW0RQWK9LVLW7DQG0RQWK
9LVLW7%RWKVWXG\GUXJDQG3 &6.LGRVHVZLOOEHDGPLQLVWH UHGRQVLWHGXULQJFOLQLFYLVLWVDIWHUDOO
SURFHGXUHVKDYHEHHQFRPSOHWHG
$QLQGHSHQGHQWH[SHUW'DWD0RQLWR ULQJ&RPPLWWHH'0&ZLOOIRUP DOO\UHYLHZDFFXPXODWLQJXQEOLQGHG
VDIHW\DQGHIILFDF\GDWDDFURVVWKHEHPSHGRLFDFLGSURJUDP

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 4 of 114 Primary Endpoint  
The primary efficacy endpoint for this study is the percent change from baseline to Month 2 in LDL -C. 
Secondary Endpoints  
1. Percent change from baseline to Month  1 in LDL -C 
2. Change from baseline to Month 1 and Month 2 in LDL -C 
3. Percent change from baseline to Month  1 and Month 2 in ApoB, non- HDL -C, TC, and hs- CRP  
4. Safety and tolerability  of bempedoic acid in this patient population over 2 months , as assessed by 
[CONTACT_20721] ( AEs) and clinical laboratory values 
Exploratory Endpoints  
Fo
r details of study assessments, see the Schedule of Events (Appendix 1).  
Number of patients (planned):  Approximately  52 adult male and female patients  
Diagnosis and Criteria for Inclusion:  
 
Key inclusion criteria  
1. Provision of written informed consent must be obtained prior to any study- specific procedure.  
2. Age ‚â•18 years or legal age of majority depending on regional law, whichever is greater at Month -4.5 
(Visit S1)  
3. Fasting, calculated LDL -C at screening (Visit  S2) ‚â•160 mg/dL and ‚â•70  mg/dL at Visit  S4 
Note:  A  single repeat of LDL -C may be completed.  For those patients who have a repeat LDL -C, 
the average of the [ADDRESS_344649] be: 
a. Naturally postmenopausal defined as ‚â•1 yea r without menses and:  
‚àí ‚â•55 years, or  
‚àí <55 years with follicle -stimulating hormone (FSH) ‚â•40.0 IU/L; or 
b. Surgically sterile including hysterectomy, bilateral oophorectomy, and/or tubal ligation; or  
c. Women of childbearing potential willing to use 2 a cceptable method s of birth control including:  
‚àí oral, implanted, topi[INVESTIGATOR_282597] 
‚àí placement  of an intrauterine device with or without hormones 
‚àí barrier  methods including condom or occlusive cap with spermicidal foam or spermicidal 
jelly 
‚àí vasectomized male partner who is the sole partner for this patient  
‚àí true abstinence:  when this is in line with the preferred and usual lifestyle of the subject. 
(Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], 
declaration of abstinence for the duration of a trial, and withdrawal are not accep table 
methods of contraception) 
There are no protocol- specific birth control requirements f or men with partners who are able to 
become pregnant. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 5 of 114 Key exclusion criteria  
1. Homozygous Familial Hypercholesterolemia (HoFH)  
2. Total fasting TG ‚â•500 mg/dL (5.6 mmol/L at Month  -3 (Visit  S2).  
Note:  A single repeat of TG may be completed.  For those patients who have a repeat TG, the 
average of the 2 values  will be used to determine eligibility.  
3. Renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic syndrome, 
including estimated glomerular filtration rate (eG FR; using central laboratory determined 
Modification of Diet in Renal Disease [MDRD] formula) <30  mL/min/1.73 m2 at Month -4.5 
(Visit S1). 
Note:  A single repeat of eGFR may be completed prior to randomization.  For those patients who 
have a repeat eGFR, the average of the 2 values will be used to determine eligibility.  
4. All patients with known cardiovascular disease (C VD) or peripheral arterial disease (PAD) or 
cerebrovascular disease (CD).   
5. History of type 1 or type  2 diabetes or laboratory evidence of diabetes ( fasting blood glucose [ FBG] 
>126 mg/d L or glycosylated hemoglobin, Type A 1C [HbA 1C] >6.5%) without prior diagnosis of 
diabetes at Month  -4.5 (Visit S1)  
6. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) >160 mmHg or diastolic 
blood pressure (DBP) >100 mmHg  at Month  -4.5 (Visit  S1).  
7. Uncontrolled hypothyroidism, including thyroid-stimulating hormone (TSH) >1.5 √ó the upper limit of 
normal (ULN) at Month -4.5  (Visit  S1).   
8. Liver disease or dysfunction, including: 
a. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ‚â• 2.0 √ó ULN at 
Month -4.5 (Visit  S1). 
b. Positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies 
(HCV -ABVivi) at Month  -4.5 (Visit  S1).  
Note:  If total bilirubin (TB) ‚â•1.2  √ó ULN, a reflex indirect (unconjugated) bilirubin will be 
obtained and if consistent with Gilbert‚Äôs disease, the patient may be enrolled in the study.   
Note:  At the discretion of the investigator, a single repeat of ALT and/or AST may be 
comple ted.  For those patients who have a repeat ALT and/or AST, the average of the 
[ADDRESS_344650] for Hepatitis  C ribonucleic acid (RNA) is negative, patien t can be enrolled.  
9. Gastrointestinal conditions or procedures (including weight loss surgery; eg, Lap- Band¬Æ or gastric 
by[CONTACT_6476]) that may affect drug absorption. 
10. History of h ematologic or coagulation disorders or a hemoglobin (Hgb) level <10 g/dL at Month -4.5 
(Visit S1)  
11. History of malignancy (except non- metastatic basal or squamous cell carcinoma of the skin and 
cervical carcinoma in situ) . 
12. Unexplained creatine kinase (CK) >3 √ó ULN at screening up to randomization (ie, not associated with 
recent trauma or physically strenuous activity).  Patients with an explained CK elevation must have 
single repeat CK ‚â§3  √ó ULN prior to randomization.   
13. History within the last [ADDRESS_344651] been stable, without evidence of abuse prescribed by [CONTACT_76759] a health care practitioner can be enr
olled after evaluation by 
[CONTACT_737].  
14. Blood donation, participation in a clinical study with multiple blood draws, major trauma, blood 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 6 of 114 transfusion, or major surgery with or without blood loss within 30  days prior to randomization  
15. Use of any experimen tal or investigational drugs within 30 days  or 5 half -lives, whichever is longer  
16. Previous enrollment in a Esperion Phase 3 bempedoic acid (ETC -1002) clinical study 
17. Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12  months prior to s creening, 
such as: anacetrapib, dalcetrapib , or evacetrapib.  
18. Use of, or a plan to initiate, these prohibited therapi[INVESTIGATOR_014]/supplements during the study: 
‚Ä¢ Mipomersen (must be stopped at least 6 months prior to Month  -4.5 [Visit  S1]),  
‚Ä¢ Lomitapi[INVESTIGATOR_282598] (must be stopped at least 3 months prior to Month  -4.5 
[Visit S1]),  
‚Ä¢ Red yeast rice containing products (must be stopped on or before Month -4.5 [Visit  S1]),  
‚Ä¢ Lipid -regulating drugs or supplements (must be stopped on or before Month  -4.5[Visit  S1]) 
19. Planned initiation or changes to the following drugs prior to Month -4.5: 
‚Ä¢ Hormone repl acement (6  weeks prior to Month  -4.5) 
‚Ä¢ Thyroid replacement (6 weeks prio r to Month  -4.5) 
‚Ä¢ Obesity medication (3  months prior to Month  -4.5) 
20. A medical or situational (ie, geographical) finding that in the investigator‚Äôs opi[INVESTIGATOR_282599]‚Äôs safety or ability to complete the study.  
21. Patient  is pregnant or breast feeding, or planning to become pregnant dur ing treatment and/ or within 
30 days  after the end of treatment  
22. An employee or contractor of the facility conducting the study, or a family member of the Principal 
Investigator, Co -Investigator, or Sponsor.  
23. Heterozygous f amilial hypercholesterolemia (HeFH)  
24. Concomitant use of a PCSK9 inhibitor ( Praluent¬Æ [alirocumab] or Repatha¬Æ [evolocumab]) at 
(Visit S1) or prior use within the past [ADDRESS_344652], dose, and mode of administration:   
‚Ä¢ Bempedoic acid 180- mg tablets/ once per day 
‚Ä¢ Matching placebo tablets /once per day  
‚Ä¢ PCSK9 i ‚Äì Repatha 420 mg injection once monthly  
All study drug (bempedoic acid or placebo) will be ingested once daily with or without food.  On clinic days patients will come to the clinic in the fasted state and the PCSK9 i and study drug will be 
administered after  all study procedures have been conducted.  PCSK9i injections must be administered 
consistently throughout the t rial within 30 ¬± 3 days from  the previous dose.  Efficacy will va ry if the 
doses are not consistently administered.  
Duration of treatment:  
The duration of treatment will be composed of a 1.5-month screening period, a 3-month PCSK9i lipid 
stabilization period, and a 2-month treatment period.  
Criteria for evaluation:  
Efficacy:  
Lipid and Cardiometabolic Assessments:  
‚Ä¢ Calculated LD L-C, non-HDL -C, TC,  ApoB,  and hs -CRP  
‚àí If TG exceeds 400  mg/dL (4.5 mmol/L) or LDL-C is ‚â§50 mg/dL (1.3 mmol/L), direct 
measure of LDL -C will be conducted. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 7 of 114 Other biomarker and PK samples:  
Pharmacokinetics  
Three pharmacokinetic (PK) samples will be collected (see lab manual).  Plasma concentrations of 
bempedoic acid and its metabolite ESP15228 will be determined in patients who are receiving bempedoic 
acid, who have compliance ‚â•80%, and who have taken a dose of bempedoic acid within 2 days of the 
sample collection.  All patients, site personnel, and study personnel will remain blinded to treatment 
assignment throughout the duration of the study.  Personnel performing the bioanalytical analysis of 
bempedoic acid concentrations will be unblinded in order t o assay the appropriate samples during the 
study.  Plasma concentrations of bempedoic acid and ESP15228 will be summarized using descri ptive 
statistics by [CONTACT_7206].  
 
Safety:  
Safety Assessments:  
‚Ä¢ Adverse events and serious adverse events ( SAEs ) will be col lected and reported .  Other safety 
assessments will include clinical safety laboratories (including hematology, blood chemistry, 
HbA 1C, fasting glucose, and urinalysis), physical examination (PE) findings, vital signs, and 
weight.  
Clinical Laboratory Assessments:  
‚Ä¢ Hematology:  Hematocrit (Hct), Hgb, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet count, red blood cell (RBC) count, white blood cell (WBC) count with differential (absolute values only)  
‚Ä¢ Urinalysis (Dipstick):  Clarity, bilirubin, color, glucose, ketones, leukocyte esterase, nitrite, occult 
blood, pH, protein, specific gravity, urobilinogen 
‚Ä¢ Urinalysis (Microscopic):  Obtain centrally only if positive urine dipstick; bacteria, casts, crystals, 
epi[INVESTIGATOR_1663], RBC, and WBC 
‚Ä¢ In patients receiving anticoagulant therapy that in the investigator‚Äôs judgement require 
monitoring, PT/international normalized ratio (INR) will be evaluated at Visit T1 and [ADDRESS_344653] Visit  T1 using a local or central lab  
‚Ä¢ Serum Chemistry (fasting):  Albumin (ALB), alkaline phosphatase (ALK- P), ALT (or serum 
glutamic pyruvic transaminase [SGPT]), AST (or serum glutamic oxaloacetic transaminase 
[SGOT]), blood urea nitrogen (BUN), calcium (Ca), carbon dioxide (CO 2), chloride (Cl), 
creatinine, CK, glucose, lactate dehydrogenase (LDH), phosphorus, potassium (K), sodium (Na), total and direct bilirubin, total protein, uric acid  
‚Ä¢ HbA
1C 
Other Screening Laboratories: 
‚Ä¢ Serum pregnancy test (only for fem ales who are of childbearing potential), TSH, FSH (in females 
naturally postmenopausal, females <55  years of age at screening) 
Safety and Monitoring:  
Post-randomization, lipid results will be masked in order to maintain the blind. 
Monitoring and Managemen t of Potential AEs and Adverse Events of Special Interest (AESI)  
Adverse Events Associated with Experience with bempedoic acid to date:  
Potential AEs:  
Based on findings in nonclinical models, potential AEs include reversible hypoglycemia and metabolic acidosis.  Potential cases of reversible hypoglycemia and metabolic acidosis will be 
identified by [CONTACT_282619].  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 8 of 114 Musculoskeletal Safety:  
Patients with CK abnormalities will also be reviewed for any other  lab changes, such as creatinine, 
and any reported AEs or SAEs.  Musculoskeletal events will be identified and evaluated by [CONTACT_282620].  
Hepatic:  
Hepatic function will be monitored throughout with the clinical safety labs.  More detailed 
investigation will occur if the safety clinical laboratory results are [ADDRESS_344654].  
Further details on occurrence and monitoring are available in the Investigator‚Äôs Brochure (IB) and 
protocol.  
Statistical methods:  
Sample Size 
The planned total sample size for this study is 52 with 26 patient s in the bempedoic acid 180 mg group 
and 26 in the placebo group.  This sample size is expected to  
  
Analysis Populations 
The Full Analysis S et (FAS), used for all of the efficacy analyses, is defined as all randomized patients 
with a baseline lipid value, at least 1 postbaseline lipid value, and having taken their study drug within 
2 days of the lipid measurement.  The FAS is also known as the modified intention- to-treat (mITT) set of 
patients.  Patients in the FAS will be included in their randomized treatment group, regardless of the 
treatment they actually received.   Other subsets of the FAS will be considered to evaluate primary and 
secondary endpoints as sensitivity analyses and the details will be described in the statistical analysis plan (SAP). 
The Safety Population (SP), used for all of the safety summaries, is defined as all randomized patients who received at least 1  dose of study medication.  Patients in the SP will be included in the treatment 
group that they actually received, regardless of  their randomized treatment.   
Primary Endpoint  
The primary efficacy endpoint is the percent change from baseline to Month  2 in LDL -C.  The primary 
efficacy endpoint will be analyzed using analysis of covariance (ANCOVA), with treatment group as a factor and baseline LDL -C as a covariate.  The details of the ANCOVA model and options to correct for 
unequal variances will be described in the SAP.  Baseline LDL -C is defined as the average of S4 and 
Day [ADDRESS_344655] (LOCF).  The least squares mean (LSM) and standard error (SE) will be provided for both treatment groups, along with the placebo- corrected LSM, its 
95% confidence interval (CI) and associated p- value.  
Secondary and Exploratory Efficacy Endpoints  
Secondary endpoints based on lipid parameters will be analyzed in the similar fashion as for the primary 
endpoint. 
Safety Analyses  
Descriptive summary will be provided for the safety data in this study.   
The su bject incidence of all treatment -emergent AEs (TEAE), SAEs, related AEs, AEs leading to 
withdrawal of study drug and/or study, fatal AEs, and AEs of special interest (AESI) will be tabulated by 
[CONTACT_9313] (SOC) and preferred term in descending order of frequency and by [CONTACT_1570]. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 9 of 114 Clinical safety laboratories, including hematology, blood chemistry, HbA 1C, glucose, and urinalysis; PE 
findings; vital signs; and weight will be summarized by [CONTACT_282621] (where appropriate) at each postbaseline time point. 
Hepatic Safety  
For liver -associated enzymes and TB, the number and percent of patients with abnormal values for ALT, 
AST, and TB will be summarized.  All liver -associated laboratory abnormalities will be assessed for Hy‚Äôs 
Law criteria (‚â•3  √ó ULN for either ALT or AST, with accompanying TB >2 √ó ULN in the absence of 
other known causes). 
Musculoskeletal Safety  
AEs of muscle related symptoms will be summarized by [CONTACT_1570].  In addition, the number and 
percent of patients with abnormal CK values will be summarized.  Finally, muscle- related AEs will be 
summarized by [CONTACT_282622]. 
Diabetes/Hyperglycemia Cases of new onset of diabetes will be recorded as AEs and will be summarized  using the appropriate 
SOC.  These events will be summarized by [CONTACT_282623]. 
Renal Safety  
Baseline eGFR and values of CK will be summarized by [CONTACT_282624].  Shift tables of eGFR category from baseline over the study, will be provided by [CONTACT_6490].   
Neurocognitive Events 
Neurocognitive events will be identified and evaluated by [CONTACT_282625].  Summarization of neurocognitive events will occur using prespecified Medical Dictionary for 
Regulatory Activities (MedDRA) terms and will b e performed by [CONTACT_1570]. 
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344656] Exclusion Criteria  ..........................................................................................28  
7.3. Investigator/Sponsor Suspension or Termination of Pat ient Enrollment ...................[ADDRESS_344657] Handling and Disposal ........................................36  
10. STUDY PROCEDURES  ............................................................................................37  
10.1.  Informed Consent .......................................................................................................37  
10.2.  Procedures and Schedule of Assessments ..................................................................37  
10.2.1.  Screening Month -4.5 (Visit S1) .................................................................................37  
10.2.2.  PCSK9i Run-in Month - 3 (Visit S2)  ..........................................................................38  
10.2.3.  PCSK9i Run-in Month - 2 (Visit S3)  ..........................................................................39  
10.2.4.  PCSK9 Run-in Month - 1 (Visit S4) ............................................................................39  
10.2.5.  Treatment Week 0 (Visit  T1; Day  1) ..........................................................................39  
10.2.6.  Treatment Month 1 (Visit T2 ¬±3 days) .......................................................................40  
10.2.7.  Treatment Month 2 (Visit T3 ¬±3 days)/EOS ..............................................................[ADDRESS_344658] Withdrawal Criteria  .......................................................................................42  
10.3.1.  Early Withdrawal from the Study ...............................................................................42  
10.3.2.  Procedures for Early Withdrawal  ...............................................................................42  
11. ASSESSMENT OF SAFETY  .....................................................................................44  
11.1.  Safety Parameters  .......................................................................................................44  
11.1.1.  Demographic/Medical History  ...................................................................................44  
11.1.2.  Vital Signs  ..................................................................................................................44  
11.1.3.  Weight, Height, and Body Mass Index  .......................................................................44  
11.1.4.  Physical Examination  .................................................................................................45  
11.1.5.  Clinical Laboratory Tests  ...........................................................................................45  
[IP_ADDRESS].  Laboratory Parameters (Safety)  ..................................................................................45  
[IP_ADDRESS].  Clinical Laboratory Tests (PK)  ...................................................................................47  
[IP_ADDRESS].  Sample Collection, Storage, and Shippi[INVESTIGATOR_007] .................................................................47  
[IP_ADDRESS].  General Monitoring and Management of Abnormal Clinical Labs  ............................47  
[IP_ADDRESS].  Monitoring and Management of Potential Hypoglycemia and Metabolic 
Acidosis ......................................................................................................................[ADDRESS_344659]  .............................................................................56  
12.4.  Data Monitoring Committee  .......................................................................................57  
12.5.  Assessment of Lipid Endpoints ..................................................................................57  
12.5.1.  Lipid Parameters  .........................................................................................................57  
12.5.2.  Clinical Laboratory Tests (Lipi[INVESTIGATOR_805])  ..............................................................................[ADDRESS_344660] ACCESS TO SOU RCE DATA/DOCUMENTS .........................................[ADDRESS_344661]/Independent Ethics Committee Approval ......................[ADDRESS_344662] OF REFERENCES  ............................................................................................71  
21. APPENDICES  ............................................................................................................72  
APPENDIX 1.  SCHEDULE OF EVENTS (SUBJECT VISIT SCHEDU LE) ...........................73  
APPENDIX 2.  SPONSOR‚ÄôS SIGNATURE  ...............................................................................76  
APPENDIX 3.  INVESTIGATOR‚ÄôS SIGNATURE ....................................................................[ADDRESS_344663] OF TABLES  
Table 1:  Abbreviations and Specialist Terms  ...........................................................................15  
Table 2:  Investigational Medicinal Products ............................................................................32  
Table 3:  Clinical Laboratory Parameters (Safety)  ....................................................................46  
Table 4:  Clinical Laboratory Parameters (Lipi[INVESTIGATOR_805]) and Cardiometabolic Biomarkers  ..............[ADDRESS_344664] terms are used in this study protocol. 
Table 1: Abbreviations and Specialist Terms   
Abbreviation or Specialist Term  Explanation 
ACL  Adenosine triphosphate -citrate lyase  
ADR  Adverse drug reaction 
AE Adverse event  
AESI  Adverse events of special interest  
ALB  Albumin 
ALK -P Alkaline phosphatase  
ALT  Alanine aminotransferase  
ANCOVA Analysis of covariance  
ApoB Apolipoprotein B 
ASCVD  Atherosclerotic cardiovascular diseases  
AST  Aspartate aminotransferase  
ATP  Adenosine triphosphate  
AUC  Area under the concentration- time curve  
AUC 0-[ADDRESS_344665] Hematocrit  
HCV  Hepatitis C virus  
HCV -AB Hepatitis C antibodies 
HeFH  Heterozygous familial hypercholesterolemia  
Hgb Hemoglobin 
HMG- CoA  3-hydroxy-3- methylglutaryl- coenzyme A  
HoFH Homozygous familial hypercholesterolemia 
hs-CRP  High -sensitivity C -reactive protein  
IB Investigator‚Äôs Brochure  
ICD Informed Consent Document 
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee 
IMP Investigational medicinal product 
IND Investigational New Drug Application  
INR International normalized ratio 
IRB Institutional Review Board  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344666] level  
non-HDL -C Non-high-density lipoprotein cholesterol  
PAD Peripheral arterial disease  
PCSK9  Proprotein convertase subtilisin/kexin type 9 
PCSK9i  PCSK9 inhibitor 
PE Physical exam ination 
PK Pharmacokinetic(s)  
PT Prothrombin time 
QM Once monthly  
RBC Red blood cell 
RNA  Ribonucleic acid 
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SBP Systolic blood pressure 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344667] operating procedures  
SP Safety population 
S[LOCATION_003]RS  Suspected and unexpected serious adverse reactions  
t¬Ω  Terminal elimination half -live 
T2DM  Type 2 diabetes mellitus  
TB Total bilirubin  
TC Total cholesterol  
TEAE  Treatment -emergent adverse event  
TG Triglycerides  
TSH  Thyroid-stimulating hormone 
TQT  Thorough QT/QTc 
ULN Upper limit of normal 
US [LOCATION_002]  
WBC  White blood cell  
WHO World Health Organization 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 19 of 114 4. INTRODUCTION 
4.1. Overview of the Disease Under Study   
Bempedoic acid (ETC -1002) is an inhibitor of adenosine triphosphate- citrate lyase (ACL) 
(adenosine triphosphate [ATP] citrate lyase), an enzyme upstream of 3-hydroxy-3- methylglutaryl 
coenzyme A (HMG -CoA) reductase in the cholesterol biosynthesis pathway.  It is an oral first-
in-class small molecule designed to lower low -density lipoprotein cholesterol (LDL- C) levels in 
patients with high cardiovascular (CV) risk unable to meet their treatment goals with currently 
available lipid -lowering therapi[INVESTIGATOR_014].  
Proprotein convertase subtilisin kexin type 9 (PCSK9) reduces LDL receptor recycling to the 
hepatic surface, thereby [CONTACT_282626].  Monoclonal 
antibodies neutralize  PCSK9 and reduce LDL -C levels when administered alone or in 
combination with other background therapi[INVESTIGATOR_014].   
Elevated LDL -C is a major modifiable risk factor for the development of atherosclerosis and 
atherosclerotic cardiovascular diseases (ASCVD) (Sharrett 2001) .  Despi[INVESTIGATOR_282600], CV disease is the number  1 cause of death globally 
(WHO 2015) .  An estimated 17.5 million people died from CV  diseases in 2012, representing 
31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart 
disease (CHD) and 6.7 million were due to stroke (WHO 2015) . Cardiovascular disease remains 
the leading cause of death among Europeans, Americans, and around the world.  The Global 
Burden of Disease study estimated that 29.6% of all deaths worldwide ( approximately 
15.6 million deaths ) were caused by [CONTACT_282627] 2010, more than all communicable, maternal, 
neonatal and nutritional disorders combined, and double the number of deaths caused by [CONTACT_282628] (Nichols 2014) .  In the [LOCATION_002]  (US), based on 2011 death rate data, more than 
2150 Americans die from CV diseases daily, an aver age of 1 death every 40  seconds.  
Approximately 155,000 Americans dying from CV disease are less than 65  years of age.  In 
2011, 34% of deaths due to CV  disease occurred prior to the age of 75  years, less than the 
current 78.7- year average life expectancy (Mozffarian 2015) . As such new therapi[INVESTIGATOR_282601]. 
Global guidelines recommend lowering o f LDL-C to levels below 100 mg/dL and often under 
70 mg/dL (Jacobson 2014)  or reduction of ‚â•50% (Stone 2013).  In order to reach these goals, 
lipid-lowering therapi[INVESTIGATOR_282602].  The combination of bempedoic acid and 
a PCSK9  inhibitor (PCSK9 i) may offer a n additional treatment option in the future for 
physicians . 
4.2. Background on Bempedoic Acid  
4.2.1. Mechanism of Action  
Bempedoic acid  is a first -in-class small molecule inhibitor of ACL, an enzyme upstream of 
HMG-CoA in the cholesterol biosynthesis pathway.  Bempedoic acid is a prodrug that requires 
activation in liver to ETC -1002- co-enzyme  A (ETC -1002- CoA) , which mediates competitive 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 20 of 114 inhibition of ACL.  Inhibition of ACL by [CONTACT_76753]-1002- CoA decreases cholesterol synthesis in liver 
leading to increased LDL  receptor (LDLR) expression and LDL particle clearance from the 
blood.  Therefore, inhibition of ACL by [CONTACT_76753]-1002-CoA reduces LDL- C via the same pathway 
as HMG -CoA reductase inhibition by [CONTACT_101818]. 
An important differentiating feature of bempedoic acid  is that it does not inhibit cholesterol 
synthesis in skeletal muscle.  In addition to preliminary data suggesting that only minor amounts 
of bempedoic acid  enter skeletal muscle (<5% of systemic exposure), skeletal muscle does not 
express the enzyme required to activate bempedoic acid  to ETC -1002-CoA and inhibit ACL.  
Therefore, bempedoic acid  is not anticipated to mediate the adverse effects associated with 
inhibition of biological intermediates within the cholesterol biosynthesis pathway in skeletal 
muscle.   The long- term safety of bempedoic acid and its metabolites regarding human skeletal 
muscle is not yet established.   
4.2.2. Nonclinical Experience 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344668] recent IB for additional information  regarding previous human 
experience.  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 23 of 114 5. TRIAL OBJECTIVES AND  PURPOSE  
5.1. Study Objectives  
5.1.1. Primary Objective  
‚Ä¢ To assess the 2-month efficacy of bempedoic acid 180  mg/day vs placebo in the 
reduction of LDL-C in patients on PCSK9i therapy  
5.1.2. Secondary Objectives  
‚Ä¢ To assess the 1-month efficacy of bempedoic acid 180  mg/day vs placebo in the 
reduction of LDL-C in patients on PCSK9i therapy  
‚Ä¢ To evaluate the effect of bempedoic acid 180 mg/day vs placebo on apolipoprotein B 
(ApoB), non- high-density lipoprotein cholesterol (non- HDL -C), total cholesterol 
(TC), and high- sensitivity C -reactive protein ( hs-CRP ) after 1 and 2 months in 
patients on PCSK9 i therapy  
‚Ä¢ To evaluate the safety and tolerability of bempedoic acid 180  mg/day c ompared to 
placebo in patients on PCSK9i therapy  
5.1.3. Exploratory Objectives  
5.1.4.
 Primary Endpoint  
The primary efficacy endpoint for this study is the percent change from baseline to Month 2 in 
LDL- C. 
5.1.5. Secondary Endpoints  
‚Ä¢ Percent change from baseline to Month 1 in LDL -C 
‚Ä¢ Change from baseline to Months 1 and 2 in LDL -C 
‚Ä¢ Percent  change from baseline to Months 1 and 2 in ApoB, non- HDL -C, TC, and 
hs-CRP   
‚Ä¢ Safety  and tolerability of bempedoic acid in this patient population over 2 months, as 
assessed by [CONTACT_282629]  
5.1.6. Exploratory Endpoints  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 24 of 114 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 25 of 114 6.  INVESTIGATIONAL PLAN  
6.1. Overall Study Design  
This is a Phase  2, randomized, double-blind, placebo-controlled, parallel group multicenter study 
that will be conducted at approxima tely 20  clinical sites in North America.  Screening 
Month -4.5 (Visit S1) will occur approximately 1 8 weeks prior to randomization.  After 
providing informed consent at Visit S1, patients will stop all background lipid- lowering therapy 
and lipid -modifying nutritional supplements, if applicable.  All patients will return to the clinic 
on Month -3 (V isit S2).  During this visit, patients with an LDL -C value ‚â•160 mg/d L (via central 
or local lab) and triglycerides <500  mg/d L (via central or local lab) will initiate PCSK9 
background therapy (Repatha 420 mg once montly [ QM]).  Sites that do not use a local lab may 
need to bring patients back for another visit to administer PCSK9 background therapy, as a 
qualifying LDL value is required prior to initiating  the 3 -month PCSK9i run -in period.  No other 
background lipid-modifying therapy except study provided PCSK9i will be permitted during the 
trial.  After 1 month (at least 30 ¬± 3 days) , patients will return to the clinic for Month -2 
(Visit S3 ) followed by [CONTACT_43380] -1 ( Visit S4 ) 30 ¬± 3 days later.  During these visits , Repatha will 
be administered, labs will be collected , and safety assessed .  At Visit S4 , LDL- C will be checked 
a second time prior to randomization.  Patients with an LDL -C ‚â•70 mg/d L (via central lab only) 
at this visit will qualify for randomization.  Patien ts with LDL -C <70  mg/dL at Visit S4 will be 
screen failed and no further PCSK9i therapy will be administered.  Day  1 should occur 30 days  ¬± 
3 days  after Visit S4, once LDL- C eligibility is establis hed.  On Day  1, qualified patients will be 
randomized 1:1 to bempedoic acid 180 mg/day (n  = 26) or matching placebo (n = 26).  
Randomized patients will return for clinic visits at Month 1 (Visit T2) and Month 2 (Visit T3).  
Both study drug and PCSK9i doses will be administered on site during clinic visits after all 
procedures have been completed.   
An independent expert Data Monitoring Committee (DMC) will formally review accumulating 
unblinded safety and efficacy data across the bempedoic acid program .  
%HPSHGRLF$FLG (VSHUL RQ7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO  $PHQGPHQW0DUFK
&RQILGHQWLDO 3DJHRI)LJXUH 6WXG\6WXG\'HVLJQ

6WXG\+\SRWKHVLV
7KHSULPDU\K\SRWKHVLVLVWKDW EHPSHGRLFDFLGZLOOUHVXOWLQJU HDWHUUHGXFWLRQRI/'/&DV
GHILQHGE\WKHPHDQSHUFHQWFK DQJHIURPEDVHOLQHDW0RQWKWK DQSODFHERZKHQXVHGLQ
FRPELQDWLRQZLWKD3&6.LLQSD WLHQWVZLWKK\SHUOLSLGHPLD
6WXG\'XUDWLRQDQG3HULRG
7KHGXUDWLRQRIWUHD WPHQWZLOOEHZHHNVPRQWKVFUHHQLQJ SHULRGDPRQWKOLSLG
VWDELOL]DWLRQSHULRGDQGPRQW KWUHDWPHQWSHULRG
(QGRI6WXG\
7KHVWXG\ZLOOHQGZKHQWKHODVW UDQGRPL]HGSDWLH QWFRPSOHWHVW KH0RQWKYLVLW7 KHHVWLPDWHG
RYHUDOOGXUDWLRQRIWKHVWXG\IL UVWSDWLHQWILUVWYLVLW>)3)9@ WRODVWSDWLHQWODVWYLVLW>/3/9@LV
DSSUR[LPDWHO\PRQWKV
1XPEHURI3DWLHQWV
7KHVWXG\ZLOOHQUROODSSUR[LPDWH O\DGXOWSDWLHQWVZLWKK\SH UOLSLGHPLD
3DWLHQW,GHQWLILFDWLRQ1XPEHUV
$XQLTXHSDWLHQWLGHQ WLILFDWLRQQXPEHUZLOO EHDVVLJQHGWRHDFK SDWLHQWE\WKHLQWHUDFWLYHZHE
UHVSRQVHV\VWHP,:56DWWKH WLPHRILQIRUPH GFRQVHQWDQGZLOO EHHQWHUHGRQDOO
GRFXPHQWDWLRQ,IDSDWLHQWLV QRWHOLJLEOHWRUHFHLYHWUHDWPH QWRULIDSDWLHQWGLVFRQWLQXHVIURP
WKHVWXG\WKHLUSDWLHQWLGHQ WLILFDWLRQQXPEHUFDQQRWEHDVVLJQ HGWRDQRWKHUSDWLHQW

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 27 of 114 6.6.1. Screening  and 1 Month  PCSK9 i Run-in Period  
Screening will occur approximately 18 weeks prior to Day 1 (Visit T1) .  Eligible patients will 
return to the clinical site at Month -3 (Visit S2) .  Du ring this visit, patients  with an LDL- C value 
‚â•160 mg/d L (via central or local lab) and triglycerides <500  mg/d L (via central or local lab) will 
initiate study-provided PCSK9 i background therapy (Repatha 420 mg QM).  No other 
background lipid-modifying therapy except study provided PCSK9i will be permitted during the 
trial.  
Patients who are deemed not eligible for randomization at any point during screening will be 
notified by [CONTACT_282630].  
As necessary, for reasons of safety if a patient begins the run-in period but screen fails prior to randomization, the patient may be asked to return to the clinical site for further evaluation and 
follow-up of AEs. 
6.6.2. Randomization and Treatment Period 
Patients who satisfy all entry criteria , complete the 1.5-month screening period and 3-month 
PCSK9 i run-in period, and have an LDL- C ‚â•70 mg/dL at S 4 will be randomized.   
Randomization numbers will be assigned via IWRS on Day 1 (Visit T1).  Patients will be 
randomized in a ratio of 1:1 to receive 1  of the following 2 treatments in a double-blind fashion 
in addition to monthly PCSK9i background therapy: 
‚Ä¢ Bempedoic acid  180- mg tablet  
‚Ä¢ Matching placebo tablet  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344669] be obtained prior to any study- specific 
procedure. 
2. Age ‚â•18 years or legal age of majority depending on regional law, whichever is greater at 
Month -4.5 (Visit S1) 
3. Fasting, calculated LDL -C at screening ( Visit S2 ) ‚â•160 mg/dL and ‚â•70 mg/dL at 
Visit S4 
Note:  A single repeat of LDL -C may be completed.  For those patients who have a repeat 
LDL-C, the average of the [ADDRESS_344670] be: 
a. Naturally postmenopausal defined as ‚â•1 year without menses and:  
‚àí  ‚â•55 years, or  
‚àí  <55 years with follicle -stimulating hormone (FSH) ‚â•40.0 IU/L; or 
b. Surgically  sterile including hysterectomy, bilateral oophorectomy, and/or tubal 
ligation; or 
c. Women of childbearing potential willing to use 2 acceptable method s of birth control 
including: ‚àí oral, implanted, topi[INVESTIGATOR_282597]  
‚àí placement  of an intrauterine device with or without hormones 
‚àí barrier  methods including condom or occlusive cap with spermicidal foam or 
spermicidal jelly  
‚àí vasectomized male partner who is the sole partner for this patient  
‚àí true abstinence:  when this is in line with the preferred and usual lifestyle of the 
subject.  (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
postovulation methods], declara tion of abstinence for the duration of a trial, and 
withdrawal are not acceptable methods of contraception.) 
There are no protocol-specific birth control requirements for men with partners who are able to become pregnant.  
7.2. Subject Exclusion Criteria  
Patient s who meet any of the following criteria will not be randomized: 
1. Homozygous Familial Hypercholesterolemia (HoFH)  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 29 of 114 2. Total fasting TG ‚â•500 mg/dL (5.6 mmol/L ) at Month -3 (Visit S2) 
Note:  A single repeat of TG may be completed prior to initiation of the single -blind Run-
in period.  For those pa tients who have a repeat TG,  the average of the 2 values will be 
used to determine eligibility.  
3. Renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic 
syndrome, including estimated glom erular filtration rate (eGFR; using central laboratory 
determined Modification of Diet in Renal Disease [MDRD] formula) 
<30 mL/min/1.73 m2 at Month -4.5 (Visit S1) 
Note:  A single repeat of eGFR may be completed prior to randomization.  For those patients who have a repeat eGFR, the average of the 2 values be used to determine 
eligibility.  
4. All patients with known cardiovascular disease (CV D) or peripheral arterial disease 
(PAD) o r cerebrovascular disease (CD)  
5. History of t ype 1 or t ype 2 diabetes or laboratory evide nce of diabetes (fasting blood 
glucose [ FBG ] >126 mg/d L or glycosylated hemoglobin, Type A 1C (HbA 1C) >6.5%) 
without prior diagnosis of diabetes at Month -4.5 (Visit S1) 
6. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) >160 mmHg 
or diastolic blood pressure (DBP) >100  mmHg  at Month -4.5 (Visit S1) 
7. Uncontrolled hypothyroidism, including thyroid-stimulating hormone (TSH) >1.5 √ó the 
upper limit of normal (ULN) at Month -4.5 (Visit S1) 
8. Liver disease or dysfunction, including: 
a. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ‚â• 2.0 √ó 
ULN at Month -4.5 (Visit  S1). 
b. Positive serology for hepatitis  B surface antigen (HBsAg) and/or hepatitis  C 
antibodies (HCV- ABVivi) at Month -4.5 (Visit S1).  
Note:  If total bilirubin ( TB) ‚â•1.2 √ó ULN, a reflex indirect (unconjugated) bilirubin 
will be obtained and if consistent with Gilbert‚Äôs disease, the patient may be enrolled 
in the study.   
Note: At the discretion of the investigator, a single repeat of ALT and/or AST may be 
completed .  For those patients who have a repeat ALT and/or AST, the average of the 
[ADDRESS_344671] for Hepatitis  C ribonucleic acid (RNA) is negativ e, patient 
can be enrolled.  
9. Gastrointestinal conditions or procedures (including weight loss surgery; eg, Lap- Band¬Æ 
or gastric by[CONTACT_6476]) that may affect drug absorption  
10. History  of hematologic or coagulation disorders or a hemoglobin (Hgb) level <10 g/dL at 
Month -4.5 (Visit S1) 
11. History  of malignancy (except non- metastatic basal or squamous cell carcinoma of the 
skin and cervical carcinoma in  situ)  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 30 of 114 12. Unexplained  creatine kinase (CK) >3  √ó ULN at screening up to randomization (ie, not 
associated with recent traum a or physically strenuous activity).  Patients with an 
explained CK elevation must have single repeat CK ‚â§3 √ó ULN prior to randomization. 
13. History within the last [ADDRESS_344672] 
been stable, without evidence of abuse prescribed by [CONTACT_76759] a health care practitioner can be enrolled after evaluation by [CONTACT_737].  
14. Blood donation, participation in a clinical study with multiple blood draws, major trauma, blood transfusion, or major surgery with or without blood loss within 30 days prior to randomization 
15. Use of any exper imental or investigational drugs within  30 days  or 5 half-lives, 
whichever is longer 
16. Previous enrollment in a n Esperion Phase 3 bempedoic acid (ETC -1002) clinical study 
17. Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to 
screening, such as: anacetrapib, dalcetrapib or evacetrapib  
18. Use of, or a plan to initiate, these prohibited therapi[INVESTIGATOR_014]/supplements during the study: 
‚Ä¢ Mipomersen (must be stopped at least 6 months prior to Month -4.5 [Visit S1]),  
‚Ä¢ Lomitapi[INVESTIGATOR_282598] (must be stopped at least 3  months prior to 
Month -4.5 [Visit S1]),  
‚Ä¢ Red yeast rice containing products (must be stopped on or before Month -4.5 
[Visit S1]),  
‚Ä¢ Lipid regulating drugs or supplements (must be stopped on or before Month -4.5 
[Visit S1])  
19. Planned  initiation or changes to the following drugs prior to Month -4.5: 
‚Ä¢ Hormone repl acement (6  weeks prior to Month -4.5 ) 
‚Ä¢ Thyroid repla cement (6  weeks prior to Month -4.5 ) 
‚Ä¢ Obesity medic ation (3 months prior to Month -4.5) 
20. A medical or situational (ie, geographical) finding that in the investigator‚Äôs opi[INVESTIGATOR_282603]‚Äôs safety o r ability to complete the study  
21. Patient  is pregnant or breast feeding, or planning to become pregnant dur ing treatment 
and/ or within 30 days  after the end of treatment  
22. An employee or contractor of the facility conducting the study, or a family member of the 
Principal Investigator, Co-Investigator, or Sponsor. 
23. Heterozygous f amilial hypercholesterolemia (HeFH)  
24. Concomitant use of a PCSK9 inhibitor (P raluent
¬Æ [alirocumab] or Repatha¬Æ 
[evolocumab]) at (Visit S1) or prior use within the past 16 weeks of Visit  S1 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 31 of 114 7.3. Investigator/Sponsor Suspension or Termination of Patient 
Enrollment  
If, in the opi[INVESTIGATOR_689], the clinical observations in the study suggest that it may be 
unwise to continue, the Investigator may suspend or terminate the study after consultation with the Sponsor (or designee).  A written statement fully docu menting the reasons for such a 
termination will be provided to the Sponsor (or designee) and the Institutional Review Board (IRB) or Independent Ethics Committee (IEC).  
The Sponsor has the right to terminate the study or to close a site and remove all study materials 
from the clinical site. A written statement will be provided to the Investigator, the IRB or IEC, 
and regulatory authorities, if required.  
Possible reasons for termination of the study at a clinical site include, but are not limited to:  
‚Ä¢ Unsatisfactory enrollment with respect to quantity or quality  
‚Ä¢ Inaccurate or incomplete data collection on a chronic basis  
‚Ä¢ Falsification of records  
‚Ä¢ Failure to adhere to the protocol 
‚Ä¢ Lack of study oversight by [CONTACT_079] [INVESTIGATOR_1238]/or designee 
If any serious or nonserious AEs have occurred at such a clinical site, all documentation relating 
to the event(s) must be obtained. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344673]  
Table 2: Investigational Medicinal Products  
Product Name:  [CONTACT_282682]:  Film -coated tablets  Film -coated tablets  
Unit Dose:  180 mg Not applicable  
Container/Closurea 35-count bottle with screw on 
childproof cap  35-count bottle with screw on childproof cap  
Route of Administration:  Oral, daily at approximately the 
same time, with or without food Oral, daily at approximately the same 
time, with or without food 
Physical Description:  
Manufacturer (Fill/Finish):  
 
Study drug should be taken once a day (once every 24 hours) at approximately the same time 
every day and may be taken with or without food.  Patients will fa st for a minimum of [ADDRESS_344674] be recorded 
with indication, total daily dose, and start and stop dates of administration.  
The Prior/Concomitant electronic case report form (eCRF) will be used to record  medications, 
herbal remedies, vitamins, other supplements, and over-the-counter medications taken within 
3 months prior to screening and during the study.  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 33 of 114 8.2.1. Prohibited Lipid -Regulating Medications and Dietary Supplements  
‚Ä¢ Patients will be required to stop taking all prescription or nonprescription drugs or 
dietary supplements taken for the purpose of lipid regulation at Month -4.5.  With the 
exception of the study provided PCSK9i (Repatha 420 mg QM), no other lipid-modifying therapi[INVESTIGATOR_282604].  
8.2.2. Allowable Medications  
‚Ä¢ Hormone replacement (if stable 6  weeks prior to Month -4.5) 
‚Ä¢ Thyroid replacement ( if stable 6  weeks prior to Month -4.5) 
‚Ä¢ Obesity medication (if stable 3  months prior to Month -4.5) 
8.3. Blinding  
Patients who satisfy all entry criteria during the screening phase and complete the PCSK9 i run-in 
period will be randomized to a treatment group  at Day  1 (Visit T1) .  The Investigator or designee 
will contact [CONTACT_282631].  The IWRS will determine 
the randomized treatment assignment number and the appropriate study drug container via 
medication identification numbers (MED  ID).  A patient is considered to be randomized when 
they have been assigned a MED ID number by [CONTACT_10966].  
After patients have been randomized, study drug, which is assigned by [CONTACT_8784], will be 
administered in a double-blind fashion.  The Sponsor, all clinical site personnel (Investigator, 
pharmacist, etc), and other vendor personnel will be blinded to the treatment group for each 
patient .  Patients will also be blinded to the treatment they receive.  Unblinded User(s) will be 
designated for each clinical site and at the sponsor (or designee) as needed.  Unblinded 
individuals will be provided IWRS access allowing t hem the ability to perform emergency 
unblinding of treatment for an individual patient.  An affirmative entry of the user‚Äôs login details will be required before the treatment group is displayed.  Unblinding at the clinical site for any 
other reason will be considered a protocol deviation.  Unblinded treatments for patients will 
NOT automatically discontinue the patient from the study.  To discontinue the patient from the 
study, the appropriate clinical site personnel will need to register the ‚Äòdiscontinuation‚Äô visit 
separately.  
Blinding of treatment must be maintained for all patients unless, in the opi[INVESTIGATOR_684], the safety of the patient may be at risk.  Only under the rarest of circumstances 
should the Investigator consider breaking the blind and only when medical/supportive care 
cannot be provided without determining if the patient is receiving active drug treatment.  In the 
event that the blind needs to be broken prior to completion of the study, the Investigator should 
contact [CONTACT_282632].  If the blind must be broken prior to 
consultation with the Medical Monitor, contact [CONTACT_282633] [ADDRESS_344675] document in the 
patient‚Äôs medical record the date, time, and reason for breaking the blind, and the names of 
personnel involved.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 34 of 114 Limited vendors (ie, the bioanalytical laboratory and other vendor personnel, if any, that are 
responsible for PK analysis) will have access to the randomization codes to facilitate  PK 
analytical wo rk, and will be instructed to not communicate in any manner information associated 
with treatment assignment to any personnel at the clinical site, the Sponsor, or contract research organization ( CRO ).  
Post-randomization values for individual laboratory m eas
 ures for LDL -C, T
C,
non-H
DL,
 ApoB, a
nd hs-CRP, including any plasma concentration of bempedoic acid and 
its metabolite  that may inadvertently suggest treatment assignment will not be available to 
personnel from the clinical site, the p atient, the Sponsor, and CRO . 
An independent DMC will monitor unblinded accumulating patient safety and efficacy data until the
 last patient has completed study treatment.   In addition, data on SAEs and deaths will be 
monitored by [CONTACT_282634].  At each DMC review, relevant unblinded safety and efficacy information from ongoing studies will be provided to the DMC by [CONTACT_10981], unblinded
p
rogrammer and statistician.  Additional details will be provided in a DMC 
Ch
arter.  
8.4. Overdose  
There is no specific antidote for an overdose of bempedoic acid.  Management of an overdose 
should be focused on the treatment of symptoms.  These symptoms should be managed 
according to current standards of care with appropriate supportive measures.  Also discontinuation of study drug should be considered, based on medical judgement. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344676] ( IMP) for this study.   The  IMP for 
this study includes bempedoic acid (180- mg film- coated tablets) and matching placebo (film -
coated tablets).  IMP will be distributed and released in accordance with regional and local 
requirements during the conduct of the study. 
PCSK9 i will be pr ovided as background therapy.  This will be dispensed and administered 
during clinic visits and will be stored and taken as commercially labeled.   
The MED ID number (an identifier on the study drug packaging) will be obtained via IWRS and 
used to select PCSK9 i and double- blind IMP for the treatment period from available clinical 
supplies at the clinical site.  
Double-blind IMP will be dispensed in 35-day supply increments to patients by [CONTACT_282635] .  Patients will receive one 35 -day supply bottle at Day  1 (Visit T1) and at  
Month 1 (Visit T2 ).  
Please see Pharmacy Manual for detailed storage requirements and management instructions.  
9.2. Administration of Investigational Medicinal Product  
Patients will be instructed to ingest IMP starting at Visit T1 for the duration of treatment period 
orally once daily (once every 24  hours) at approximately the same time each day with water.   
IMP may be taken with or without food.  On clinic visit days, patients will be instructed to delay ingestion of IMP until all study procedures have been completed.  If a patient arrive s at clinic on 
Visits  T1, T2 , or T3  without having fasted or having taken IMP before arriving at the clinic, 
reschedule the visit (the next day or as soon as possible) so that the fasting and dosing requirements have been met.  Patients will be instructed to return all packaging and unused IMP 
at each clinic visit.  
If the patient forgets to take IMP at the usual time  on nonclinic visit days, it may be taken up to 
12 hours later the same day.  After that time, the patient should not take IMP that day and should 
resume ingestion of IMP the following day.  If a patient fails to take IMP , details describing the 
reasons for nondosing should be documented in the patient‚Äôs medical records and eCRF.  Extra IMP (7  extra days per bottle) is provided and can be used, if needed, prior to the next visit or to 
replace a dose of IMP that cannot be used because it is lost or damaged.  
PCSK9 i will be administered on site at Visits S2, S3, S4, T1 , and T2.  Doses will be stored and 
administered as required in prescribing information  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344677] Accountability 
Accurate records of the receipt of all IMP and PCSK9i shipped by [CONTACT_1034] (or designee) and 
the disposition of the IMP and PCSK9 must be maintained.  
IMP records or logs must comply with applicable regulations, local law, and guidelines, and 
should include: 
‚Ä¢ Amount received/placed in storage area  
‚Ä¢ Amount currently in storage area 
‚Ä¢ MED ID number for all IMP  
‚Ä¢ Dates and initials of person(s) responsible for IMP /PCSK9 i inventory (including 
entry/movement/disposition) 
‚Ä¢ Date and amount of IMP /PCSK9 i dispensed to each patient, including unique patient 
identifiers  
‚Ä¢ Date that IMP /PCSK9 i was returned by [CONTACT_4676], assessment of compliance, and 
relevant documentation of discrepancies  
‚Ä¢ Nonstudy disposition (eg, lost, broken, wasted) 
‚Ä¢ Amount returned to Sponsor/Sponsor‚Äôs designee/destroyed or amount destroyed per 
local  standard operating procedure (SOP) following accountability by [CONTACT_76763]. 
9.4. Investigational Medicinal Product Handling and Disposal  
Upon completion or termination of the study, all used and unused IMP with the IMP packaging 
must be returned to the Sponsor (or designee) for eventual destruction unless otherwise 
authorized by [CONTACT_1034].  All IMP returns must be accompanied by [CONTACT_282636]. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344678] be adequately informed of the nature and risks of the study and understand the 
informed consent document (ICD).  No study-related procedure will be performed until the patient has been completely informed of the study, has freely consented to take part in the study, 
and has signed and dated an ICD approved by [CONTACT_1034] (or designee) and the IRB or IEC.   
10.2. Procedures and Schedule of Assessments 
Patients who provide informed consent and sign the ICD will be eligible to begin screening for the study.  The study is comprised of [ADDRESS_344679] periods:  screening , PCSK9 i run-in and double-
blind treatment.  
The schedule of study events is provided in Appendix 1.  However, a patient can be seen at any time for reasons of safety.  
Data will be captured on eCRFs.  Randomization, drug supply (re)orde ring, and patient tracking 
will occur via IWRS.   Instructions for these systems will be provided separately. 
10.2.1. Screening Month -4.5 (Visit S1 ) 
The screening period will begin with a screening visit that will occur approximately 1 8 weeks 
prior to randomization.  Visit S1 will allow the Investigator to assess the patient‚Äôs preliminary eligibility.  After the patient provides written informed consent (see Section  10.1) , the patient 
will undergo the following assessments and procedures at Visit S1: 
‚Ä¢ Demographics 
‚Ä¢ Clinically relevan t medical history   
‚Ä¢ Concomitant and prohibited medication review 
‚Ä¢ Height (cm), weight (kg), body mass index ( BMI )  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations:  
‚àí Hematolog y, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calcula ted 
 LDL- C, , non- HDL -C, , 
an d ) 
‚àí HbA 1C 
‚àí TSH  
‚àí FSH (in appropriate female patients)  
‚àí Serum pregnancy test (on appropriate female patients)  
‚Ä¢ Serology (including HBsAg, Hepatitis  C virus [ HCV] )  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 38 of 114 ‚Ä¢ Review of all inclusion/exclusion criteria that can be assessed at this time  
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Contact [CONTACT_282637] S1 central 
clinical laboratory results (available several days after Visit S1) will be instructed to washout of 
all lipid -regulating drugs and supplements and to maintain consistent diet and exercise patterns 
throughout the study.  Patients who fail to meet any entry criterio n that can be assessed at 
Visit S1 are considered to be screen failures and are not required to return for additional visits 
(although a patient can be seen at any time for safety reasons).  
10.2.2. PCSK9 i Run -in Month -3 (Visit  S2) 
Prior to scheduling Visit S2, review the screening clinical results to evaluate whether the patient 
continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit S2  and proceed with the 
Visit S2 procedures 
The patient will undergo the following assessments and procedures at (Visit S2 ) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Physical exam ination (PE) 
‚Ä¢ Vital signs  
‚Ä¢ Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C,  , 
non-HDL -C, , and ) 
‚Ä¢ ApoB a
nd hs- CRP   
‚Ä¢ First PCSK9 i monthly injection.  Verification of lipid entry criteria (LDL -C value of 
>160 mg/d L and triglycerides <500 mg/d L) must be obtained before starting PCSK9 i 
‚Ä¢ Schedule next visit (S3 has to be at least 30 days ¬± [ADDRESS_344680] dose of 
PCSK9)   
‚àí PCSK9i injections must be administered consistently throughout the trial within 
30 ¬± 3 days from the previous dose.  Efficacy will va ry if the doses are not 
consistently administered.  
Note:   Local labs can be used to assess LDL -C  and TGs
 for entry.  All other labs must be 
run vi
a the central lab.  If using a central lab or a local lab with a delay in obtaining 
results, an optional visit to administer P CSK9 may be scheduled.  Patients need to be on 
Repatha  [ADDRESS_344681] 30 days ¬± 3 days before conducting Visit  S3. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 39 of 114 10.2.3. PCSK9 i Run -in Month -2 (Visit S3) 
Prior to scheduling Visit S3, review the screening clinical results to evaluate whether the patient 
continues to meet eligibility criteria.  
‚Ä¢ If the patient continues to meet  eligibility criteria, then schedule Visit S3  and proceed 
with Visit S3  procedures 
The patient will undergo the following assessments and procedures at (Visit S3 ) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Vital signs  
‚Ä¢ Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL C,  non-HDL C, , a nd ) 
‚Ä¢ PCSK9
i monthly injection  must be given at the end of procedures 
10.2.4. PCSK9 Run -in Month -1 (Visit S4)  
One month (30 ¬± 3 days ) from S 3, patients will have their LDL -C evaluat ed a second time via 
central lab only  prior to randomization on Day 1. 
The patient will undergo the following assessments and procedures at (Visit S4) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Vital signs  
‚Ä¢ Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL C, , non-HDL C, , a nd ) 
‚Ä¢ Schedule next visit Day  1 (Day  1 should occu r 30 ¬± 3 days after S 4, once LDL -C 
eligibility [‚â•70  mg/dL ] is established ) 
‚Ä¢ PCSK9i monthly injection  must be given at the end of procedures 
10.2.5. Treatment Week 0 (Visit  T1; Day 1) 
Prior to scheduling Visit T1, review S1, S2, S3, and S4 clinical results to evaluate whether the 
patient continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit T1 and proceed with 
the Visit T1 procedures 
If the patient has met all inclusion criteria , none of the exclusion criteria, and has been on 
Repatha 420 mg for 30 ¬± [ADDRESS_344682] dose.  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 40 of 114 The patient will undergo the following assessments and procedures at (Visit T1)  
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of  the informed consent document) 
‚Ä¢ Weight  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
Note:  Urine pregnancy test (for females of childbearing potential) 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calcul ated LDL -C, , non- HD
L-C, , an d ) 
‚àí ApoB and hs- CRP  
‚àí Hb
A1C  
‚Ä¢ Predose PK  
‚Ä¢ Review inclusion/exclusion criteria to establish patient eligibility .  Patient must have 
an LDL -C ‚â•70 mg/dL  at S4 before they can be randomized  on Day 1. 
‚Ä¢ Conduct diet and exercise counseling  
‚Ä¢ IWRS contact [CONTACT_282638]-blind study drug 
‚Ä¢ Dispense IMP and provide dosing instructions ( 35-day supply bottles) 
‚àí Subject should be randomized and receive IMP  within 3 0 ¬± 3 days of S4 , as 
soon as the fi nal LDL -C entry criterion is met 
‚Ä¢ PCSK9 i injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit 
10.2.6. Treatment Month 1  (Visit T2  ¬±3 days) 
If the patient is withdrawing early from the study at this visit, proceed to Section  10.3.[ADDRESS_344683] of the required assessments.  
Patients will undergo the following assessments and procedures at Month 1 (Visit T2):  
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs since last visit (ongoing) 
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 41 of 114 ‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , an d ) 
‚àí ApoB and hs- CRP  
‚Ä¢
 Predose PK .  Should be taken ideally within 4 hours of the patient‚Äôs normal time of 
dosing 
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Return of IMP; assessment and recording of IMP compliance 
‚Ä¢ Dispense IMP and provide dosing instructions ( 35-day supply bottles)  
‚Ä¢ PCSK9 i injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit 
10.2.7. Treatment Month 2  (Visit T3  ¬±3 days) /EOS  
If the patient is withdrawing early from the study at this visit, proceed to Section  10.3.[ADDRESS_344684] of the required assessments.    
Patients will undergo the following asses sments and procedures at Month 2 (Visit T3 ): 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs since last visit (ongoing)  
‚Ä¢ PE 
‚Ä¢ Weight  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non-HDL -C, , and ) 
‚àí ApoB
 and hs- CRP  
‚àí HbA 1C 
‚Ä¢ Predose PK .  Should be taken ideally within 4  hours of the patient‚Äôs normal time of 
dosing 
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Return of IMP; assessment and recording of IMP compliance 
‚Ä¢ Complete study status in IWRS (ie, completed study).  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344685] scheduled visit at Month 2 (Visit T3 ) to be 
considered as having completed participation in the study.  
Patients who temporarily withdraw from IMP prior to Month 2 (Visit T3 ) for any reason may 
restart IMP providing that 1) the patient and the investigator are in agreement regarding this 
course of action, 2) the p atient has been off of IMP for 2 weeks or less; and 3)  IMP can be started 
as soon as possible.  For cases where the patient has been off of IMP for more than [ADDRESS_344686] the medical monitor for approval prior to restarting IMP. 
The patient‚Äôs decision to participate in the clinical study is voluntary.   Patients may refuse to 
continue in the study and/or withdraw from participation in this study at any time, for any reason, 
specified or unspecified, and without penalty or loss of benefits to which the patient is otherwise 
entitled.  
It is the right and duty of the Investigator to interrupt the treatment of any patient whose health or 
well-being may be threatened by [CONTACT_94597].  Such patients should be withdrawn 
from the study and should not be continued under a modified regimen. 
Patients who are withdrawn from the study may not re-enter.  The reasons for withdrawal from 
this study may include:  
‚Ä¢ Patient‚Äôs  withdrawal of consent 
‚Ä¢ Failure  to comply with the protocol 
‚Ä¢ Lost to follow-up 
‚Ä¢ Illness , condition, or procedural complication (including AEs) affecting the patient‚Äôs 
ability to participate or r equiring prohibited medication 
‚Ä¢ The Sponsor or Investigator terminates the study  
‚Ä¢ In the Investigator‚Äôs judgment, it is deemed in the best interest of the patient to discontinue his/her participation in the study 
‚Ä¢ Any other reason 
If a patient is lost to follow- up, every reasonable effort must be made by [CONTACT_282639]/withdrawal.  The 
measures taken to follow -up must be documented. 
10.3.2. Procedures for Early Withdrawal  
If a patient withdraws or is removed from the study for any reason, all End of S tudy procedures 
should be completed.  Reason for withdrawal, date of the discontinuation, and date of the last dose of study drug should be recorded in the appropriate section of the eCRF.  Additionally, the 
discontinuation visit date must be registered in IWRS.   Study drug assigned to the withdrawn 
patient may not be assigned to another patient. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344687] each patient complete all study visits on schedul e according to 
the protocol.  Accommodations for early or late visits in special circumstances will be considered 
by [CONTACT_282640].  Written notice (regardless of cause) is to be 
provided within 48 hours of the withdrawal to the Sponsor personnel or the Medical Monitor.  At the time of discontinuation, every effort should be made to ensure all relevant procedures and 
evaluations scheduled for the final study visit are performed.  Except in the case of a medical 
emergency, the procedures and assessments detailed in Section  10.2.7 will be performed upon 
the discontinuation of the study. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 44 of 114 11. ASSESSMENT OF SAFETY 
11.1. Safety Parameters  
At all clinic visits, investigators will review all safety information including vital signs, A Es, and 
concomitant medications and will ensure that the collected data are recorded into the appropriate 
eCRF.   Additionally, clinical laboratory samples will be collected and sent for analysis and the 
investigator will review the results to ensure continued patient safety while participating in the 
study.  
11.1.1. Demographic/Medical History  
Demographic data and a complete medical history will be obtained from the patient.  For medical 
history, conditions that are relevant and/or clinically significant should be captured with at least a 
start date (month and year) and whether the condition is ongoing or resolved.  All surgeries 
regardless of date should be reported.  
11.1.2. Vital Signs  
Vital signs will include DBP and SBP as well as heart rate.  
The patient should sit qui etly for 5  minutes prior to collection of vital signs.  At all time points, 
vitals will be collected prior to blood collection.  Blood pressure (BP)  and heart rate will be 
measured using a calibrated, fully automated machine with a cuff that is appropriate to the size 
of the upper arm.  If a fully automated machine is not available, BP may be measured manually.  
The same method (either automated or manual) and the same arm (right or left) must be used throughout the study.  The patient should be in a seated  position with feet touching the floor.  
Patients should be seated quietly for at least 5  minutes in a chair with their backs supported, their 
feet flat on the ground, and their arms bared and supported at heart level. 
11.1.3. Weight, Height, and Body Mass Index 
Weight will be measured on a calibrated scale while fasted and after voiding.  Body weight will 
be measured while fasting, using consistent scales, after voiding, and without shoes and 
outerwear (eg, coats) .  
Height will be measured using standard clinic pr ocedures.  
BMI will be calculated using the formula:  
BMI (kg/m
2) = weight in kg  / (height in meters)2 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 45 of 114 11.1.4. Physical Examination 
PEs will include an assessment of the following:  
‚Ä¢ General appearance  
‚Ä¢ Skin 
‚Ä¢ Eyes, ears, nose, and throat 
‚Ä¢ Head and neck  
‚Ä¢ Extremities  
‚Ä¢ Musculoskeletal examination  
‚Ä¢ Respi[INVESTIGATOR_76739]  
‚Ä¢ Cardiovascular assessment, including rhythm and presence of cardiac abnormalities 
‚Ä¢ Abdominal examination  
‚Ä¢ Neurologic examination including documentation of the presence of abnormalities in 
mental status and  motor and sensory function 
‚Ä¢ Any additional assessments necessary to establish baseline status or evaluate symptoms or adverse experiences 
Documentation of the PE findings will be included in the source documentation at the clinical site.  Significant findings prior to the time of ICF signature  [CONTACT_282683]/Current Medical Conditions page of the eCRF.  Only changes from baseline PE findings 
that meet the definition of an AE will be recorded on the AE page of the eCRF. 
Note:  Additi onal information will be collected regarding muscle -related AEs.  See Section  12.3. 
11.1.5. Clinical Laboratory Tests 
[IP_ADDRESS]. Laboratory Parameters (Safety) 
Patient s will be in a seated position during the blood collection.  Clinical laboratory parameters 
and tests will include those listed in  Table 3.  Collection schedule, schedule of laboratory 
parameters by [CONTACT_765], and instructions are in the Clinical Laboratory Manual provided by [CONTACT_282641].  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 46 of 114 Table 3: Clinical Laboratory Parameters (Safety)  
Clinical Laboratory Test Clinical Laboratory Test 
Hematology 
‚Ä¢ Hematocrit (Hct)  
‚Ä¢ Hemoglobin (Hgb) 
‚Ä¢ Mean corpuscular hemoglobin (MCH) 
‚Ä¢ Mean corpuscular hemoglobin 
concentration (MCHC)  
‚Ä¢ Mean corpuscular volume (MCV)  
‚Ä¢ Platelet count 
‚Ä¢ Red blood (RBC) cell count 
‚Ä¢ White blood (WBC) cell count w ith 
differential (absolute and %)  Blood Chemistry (serum, fasting) 
‚Ä¢ Albumin (Alb) 
‚Ä¢ Alkaline phosphatase (A LK-P) 
‚Ä¢ Alanine aminotransferase (ALT; SGPT)  
‚Ä¢ Aspartate aminotransferase (AST; SGOT)  
‚Ä¢ Blood urea nitrogen (BUN) 
‚Ä¢ Calcium (Ca)  
‚Ä¢ Carbon dioxide (CO2)  
‚Ä¢ Chloride (Cl) 
‚Ä¢ Creatinine  
‚Ä¢ Creatine kinase (CK)  
‚Ä¢ Glucose 
‚Ä¢ Lactate dehydrogenase (LDH) 
‚Ä¢ Phosphorus 
‚Ä¢ Potassium (K) 
‚Ä¢ Sodium (Na) 
‚Ä¢ Total and direct bilirubin (TB)a 
‚Ä¢ Total protein  
‚Ä¢ Uric acid  
Coagulation ‚Äîonly in patients receiving anticoagulant 
therapy that in the investigator‚Äôs judgment require 
monitoring at T1 and [ADDRESS_344688] -T1 
‚Ä¢ Prothrombin  time (PT)  
‚Ä¢ International  normalized ration (INR)  Urinalysis (Dipstick)  
‚Ä¢ Clarity  
‚Ä¢ Bilirubin  
‚Ä¢ Color 
‚Ä¢ Glucose 
‚Ä¢ Ketones 
‚Ä¢ Leukocyte esterase  
‚Ä¢ Nitrate  
‚Ä¢ Occult blood 
‚Ä¢ pH 
‚Ä¢ Protein  
‚Ä¢ Specific gravity  
‚Ä¢ Urobilinogen 
Urinalysis (Microscopic) -only if urine dipstick 
abnormal 
‚Ä¢ Bacteria  
‚Ä¢ Casts  
‚Ä¢ Crystals  
‚Ä¢ Epi[INVESTIGATOR_1663]  
‚Ä¢ Red blood cell (RBC)  
‚Ä¢ WBC Additional samples 
‚Ä¢ Hem oglobin A 1C (HbA 1C) 
‚Ä¢ PK 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 47 of 114 Table 3: Clinical Laboratory Parameters (Safety)  
Clinical Laboratory Test Clinical Laboratory Test 
Other Screening Labs  
‚Ä¢ Hepatitis B surface antigen (HBsAg), 
hepatitis C virus (HCV)b 
‚Ä¢ Serum pregnancy test (only for females of 
childbearing potential) 
‚Ä¢ Follicle -stimulating hormone (FSH; 
Females <55  years and >1  year without 
menses)  
‚Ä¢ Urine pregnancy test prior to randomization (for female of child bearing 
potential)  
‚Ä¢ Thyro id-stimulating hormone (TSH) 
a If TB ‚â•1.2  √ó ULN, a reflex indirect (unconjugated) bilirubin will be obtained.  
b If HCV -AB is positive, a reflex HCV RNA will be performed to rule out active disease.  
[IP_ADDRESS]. Clinical Laboratory Tests (PK) 
Trough PK  plasma concentrations of bempedoic acid and its metabolite ESP15228 will be 
collected prior to dosing at V isits T1, T2, and T3.  See lab manual for additional details.  
Patients will be in a seated positio n during the blood collection.  Collection schedule and 
instructions are provided in the Clinical Laboratory Manual.  A description of the sample 
collection, storage, and shippi[INVESTIGATOR_282605]  [IP_ADDRESS]. 
[IP_ADDRESS]. Sample Collection, Storage, and Shippi[INVESTIGATOR_282606] a separate laboratory manual provided by [CONTACT_15622].  Samples 
will be processed by [CONTACT_15622], and PK samples will be forwarded to the 
Bioanalytical Laboratory for analysis.   
Blood draws for lipi[INVESTIGATOR_805], , and glucose must meet the criteria listed below.  If 
 these criteria 
have not been met, these blood samples will NOT be collected.  If these criteria can be met by 
[CONTACT_282642] 3  days, the lipid, , and/or glucose blood samples 
will be collected at the rescheduled clinic v isit only.  
‚Ä¢ Bloo
d samples will be drawn after a minimum [ADDRESS_344689] (water is allowed) 
[IP_ADDRESS]. General Monitoring and Management of Abnormal Clinical Labs 
It is the Investigator‚Äôs responsibility to review the results of all laboratory tests as they become 
availab le and to sign and date the report to document their review.  For each laboratory test 
outside of the laboratory normal range, the Investigator needs to ascertain if this is a clinically 
significant change from baseline for the individual patient.  The Investigator may repeat the 
laboratory test or request additional tests to verify the results of the original laboratory test.  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344690] are outlined in the 
sections below. 
[IP_ADDRESS].1. Monitoring and Management of Elevated Liver Function Tes ts 
If at any time after randomization a patient experiences a new ALT and/or AST >3  √ó ULN, the 
patient will undergo repeat confirmatory liver function test (LFT) assessment as soon as is 
reasonably possible, preferably within 3 to 7 days of the laboratory result becoming available.  
Repeat LFT assessment will include:  1) measurement of ALT, AST, alkaline phosphatase, total 
and direct bilirubin, prothrombin time (PT)/international normalized ratio (INR), eosinophil count, CK, antihepatitis A virus (total), HBsAg (confirmation of screening measurement), HCV 
(confirmation of screening measurement), and anticytomegalovirus/immunoglobulin M; 
2) history of concomitant medication use; 3) history of exposure to environmental chemical agents, including ethanol; and 4) query for related symptoms.  Additionally, further testing such 
as liver ultrasound or magnetic resonance imaging ( MRI ) scanning may be warranted to rule out 
additional pathology depending on clinical presentation and should be discussed with the 
Sponsor personnel or the authorized Medical Monitor.  
‚Ä¢ If repeat LFT assessment confirms ALT and/or AST >3  √ó ULN, consideration should 
be given to withdrawing the patient and administering no further doses of study drug.  
At the investigator‚Äôs discretion, study d rug may be interrupted and the patient 
rechallenged with study drug after LFTs have returned to baseline levels.  
‚Ä¢ If repeat LFT assessment confirms ALT and/or AST >5  √ó ULN, patient should be 
withdrawn from IMP treatment,  but will be asked to continue to be followed for 
safety using the protocol- specified visit schedule (see Appendix 1) . 
‚Ä¢ If repeat LFT assessment confirms ALT and/or AST >3  √ó ULN in addition to any of 
the following, the patient should be given no further IMP treatment, but will be asked 
to continue to be followed for safety using the protocol- specified visit schedule (see 
Appendix 1) : 
‚àí TB >2  √ó ULN  
Note:  In the case of patients with Gilbert‚Äôs disease, TB will be fractionated and 
the determination of 2 √ó ULN will be based upon direct (conjugated) bilirubin. 
‚àí INR >1.5 √ó ULN (unless th e patient is on stable dose of anticoagulation 
medication)  
‚àí Appearance or worsening of right upper abdominal discomfort, anorexia, fatigue, 
nausea, vomiting, fever, rash, or eosinophilia 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 49 of 114 [IP_ADDRESS].2. Monitoring and Management of Elevated Serum Creatinine 
If at any time after randomization, a patient experiences a decrease in eGFR to the level of 
15 mL/min/1.73 m2) or if the patient experiences acute renal failure, the patient should be 
withdrawn from IMP treatment but will be asked to continue to be followed for safety using the 
protocol- specified visit schedule (see Appendix 1 ) 
[IP_ADDRESS].3. Monitoring and Management of Elevated Creatine Kinase 
If at any time after randomization  a patient experiences a marked CK elevation >5 √ó ULN, the 
patient will undergo repeat confirmatory assessment as soon as is reasonably possible, preferably 
within 3  to 7 days of the laboratory result becoming available.  
Repeat CK assessment will include query for related symptoms.  
‚Ä¢ If the repeat CK assessment confirms an unexplained (ie, not associated with recent 
trauma or physically strenuous activity) CK abnormality >5 √ó ULN, if asymptomatic , 
the patient should receive further assessment and investigation into the cause, assess 
whether there is renal injury , and measure CK approximately weekly or more 
frequently if clinically indicated until resolution.  If CK levels continue to rise; IMP 
should be discontinued.  
‚Ä¢ If sym ptomatic, the following should be completed: 
‚àí Hold IMP  
‚àí Clarification of the nature, duration, and intensity of muscle symptoms 
‚àí Review possible predisposing factors, such as unaccustomed exercise, heavy 
alcohol intake, viral illness (consider performing serology)  
‚àí Evaluation for additional diagnoses or other conditions which can cause 
myopathy including muscle tenderness (by [CONTACT_153056]), weakness, rash, measurement of 
serum creatinine, dipstick urinalysis with microscopy if indicated  
‚àí Obtain clinical chemistries to assess the possibility of lactic acidosis  
‚àí Follow symptoms and CK until the abnormality has resolved 
‚àí If based on the above evaluation an alternative explanation is suspected, consideration can be given to resuming IMP once CK returns to baseline levels 
‚àí If no alternative explanation exists, consideration should be given to withdrawing the patient from IMP treatment.  
‚Ä¢ If the repeat CK assessment confirms an unexplained (ie, not associated with recent trauma or physically strenuous activity) CK abnormality as listed below, the patient 
should be withdrawn and given no further doses of study drug:  
‚àí >10 √ó ULN, even in the absence of symptoms.  
‚àí In all cases, evaluate the signs/s ymptoms and laboratory evaluations as outlined 
above. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 50 of 114 ‚Ä¢ If the patient is withdrawn from IMP treatment, the patient should be asked to 
continue being followed for safety using the protocol- specified visit schedule (see 
Appendix 1).  
[IP_ADDRESS]. Monitoring and Management of Potential Hypoglycemia and Metabolic Acidosis 
Patients will be educated on the signs and symptoms of hypoglycemia.  If such signs and 
symptoms are  experienced, patients will be instructed to report these signs and symptoms to the 
investigator.  
During each study visit, patients will be reminded to report all signs and symptoms associated 
with hypoglycemia to the investigator.  For each occurrence of patient -reported signs and 
symptoms associated with hypoglycemia, the investigator will discuss these symptoms with the 
patient and assess whether they are attributable to hypoglycemia or to another potential cause.  
All investigator -confirmed occurrences of hypoglycemia will be recorded as an AE.  All 
occurrences of signs and symptoms that are not confirmed by [CONTACT_282643]. 
Clinical laboratories will be assessed to det ermine any signs of anion gap metabolic acidosis.  If 
laboratories are consistent with metabolic acidosis, immediate follow up with the patient for 
further medical evaluation of the acidosis will occur.  This event should be captured as an AE.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344691] a 
causal relationship with treatment.  The investigator is responsible for ensuring that any adverse 
events observed by [CONTACT_282644]‚Äôs 
medical record.  
An AE can be:  
‚Ä¢ Any unfavorable and unintended sign/symptom, including an abnormal laboratory 
finding, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product 
‚Ä¢ Any new disease or exacerbation of an existing disease  
‚Ä¢ Laboratory abnormali ty or diagnostic test abnormalities (eg, x -ray) should be reported 
as an AE if one of the following occurs   
‚àí Treatment required due to the abnormality 
‚àí Discontinuation of IMP 
‚àí Per Investigator judgement 
‚Ä¢ TEAEs are defined as AEs that begin or worsen after the first dose of study drug 
administration, as defined in the S tatistical Analysis Plan (SAP). 
12.1.2. Adverse Drug Reaction  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered an adverse drug reaction (ADR).  ‚ÄúResponses‚Äù to a medicinal product means that a 
causal relationship between the medicinal product and an AE is at least a reasonable possibility 
(ie, the relationship cannot be ruled out). 
An unexpected ADR is defined as an adverse reaction, the nature or severity of which is not consistent with the applicable product information (eg, IB for an unapproved investigational product or package insert/summary of product characteristics for an approved product). 
12.1.3. Reporting for Adverse Events  
All AEs occurring duri ng the course of the study (starting from signing informed consent 
through [ADDRESS_344692] dose of study treatment) will be collected on the AE eCRF.  Patients 
should be instructed to report any AE that they experience to the investigator.  Investigator s 
should make an assessment for AEs at each visit and record the event on the appropriate AE 
eCRF.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 52 of 114 Wherever possible, a specific disease or syndrome rather than individual associated signs and 
symptoms should be identified by [CONTACT_256299].  A cluster of signs 
and symptoms that results from a single cause should be reported as a single AE (eg, fever, 
elevated white blood cells [WBC], cough, abnormal chest x- ray, etc, can all be reported as 
‚Äúpneumonia‚Äù if that is the final diagno sis).  However, if an observed or reported sign or symptom 
is not considered a component of a specific disease or syndrome by [CONTACT_093], it should be recorded as a separate AE on the eCRF.  Additionally, the condition that led to a medical or 
surgic al procedure should be recorded as the AE, not the procedure itself .  
Any medical condition already present at screening or baseline should not be reported as an AE unless the medical condition or signs or symptoms present at baseline worsens in severity o r 
seriousness at any time during the study.  In this case, it should be reported as an AE. 
Clinically significant abnormal laboratory or other examination findings that are detected during 
the study or are present at baseline and significantly worsen during the study should be reported as AEs , as described below .  The investigator will exercise his or her medical and scientific 
judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.  Significant abnormal laboratory values occurring during the clinical study 
will be followed until repeat tests return to normal, stabilize, or are no longer clinically 
significant.  Any abnormal test that is determined to be an error does not require reporting as an 
AE. 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an AE only if any one of the following criteria is met: 
‚Ä¢ an action on the study drug is made as a result of the abnormality 
‚Ä¢ intervention for management of the abnor mality is required  
‚Ä¢ at the discretion of the investigator should the abnormality be deemed clinically 
significant  
Each AE is to be evaluated for duration, severity, seriousness, and causal relationship to the IMP.  
For each AE, the following information will be recorded: 
‚Ä¢ Description of the event (eg, headache)  
‚Ä¢ Date of onset  
‚Ä¢ Date of resolution (or that the event is continuing) 
‚Ä¢ Action taken as a result of the event  
‚Ä¢ Seriousness of the event 
‚Ä¢ Severity of the event  
‚Ä¢ Outcome of the event  
‚Ä¢ Investigator‚Äôs assessment of  relationship to IMP or PCSK9 i. 
The investigator will carefully evaluate the comments of the patient and the response to treatment in order that he/she may judge the true nature and severity of the AE.  The question of 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 53 of 114 the relationship of AEs to IMP administration should be determined by [CONTACT_282645].  
12.1.4. Severity  
It is the investigator‚Äôs responsibility to assess the intensity (severity) of an AE.  
The severity of the AE will be  characterized as mild, moderate, or severe according to the 
following definitions: 
‚Ä¢ Mild:  Events are usually transient and do not interfere with the patient‚Äôs daily 
activities  
‚Ä¢ Moderate:  Events introduce a low level of inconvenience or concern to the patient 
and may interfere with daily activities  
‚Ä¢ Severe:  Events interrupt the patient‚Äôs usual daily activity, are incapacitating with 
inability to do usual activities, or significantly affect clinical status and warrant 
intervention and/or close follow-up  
Note:  A severe AE need not be serious and an SAE need not, by [CONTACT_108], be severe. 
12.1.5. Relationship  
It is the investigator‚Äôs responsibility to assess the relationship between the IMP and the AE.  The 
degree of ‚Äúrelatedness‚Äù of the AE to the IMP may be described using the following scale:  
‚Ä¢ Not Related:  No temporal association and other etiologies are likely the cause  
‚Ä¢ Unlikely:  While cannot be definitively ruled as not related to IMP, a causal 
association is remote, and other etiologies are more likely to be the cause.  For reporting and summarization, events assessed as Unlikely to be related to IMP will be consi dered as Not Related to IMP.  
‚Ä¢ Possible:  Temporal association, but other etiologies are likely the cause.  However, 
involvement of the IMP cannot be excluded. 
‚Ä¢ Probable:  Temporal association, other etiologies are possible but unlikely.  The event 
may respond if the IMP is discontinued. 
‚Ä¢ Definite:  Established temporal association with administration of the IMP with no 
other more probable cause.  Typi[INVESTIGATOR_897], the event should resolve when the IMP is discontinued and recur on rechallenge. 
12.1.6. Monitoring and Follow- up of Adverse Events  
Patients having AEs will be monitored with relevant clinical as sessments and laboratory tests, as 
determined by [CONTACT_093].  All follow -up results are to be reported to the Sponsor personnel 
or the authorized Medical Monitor.  Any actions taken and follow up results must be recorded 
either on the appropriate page of the eCRF or in appropriate follow-up written correspondence, 
as well as in the patient‚Äôs source documentation.  Follow-up laboratory results should be filed with the patient‚Äôs source documentation. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344693] be repeated at appropriate intervals until final resolution or 
stabilization of the event(s).  
Patients with AEs related to IMP that are ongoing at study discontinuation or completio n must be 
followed until resolution, until deemed stable/chronic, or for [ADDRESS_344694], with the exception of patients reporting SAEs (see Section  12.2.2).  
12.1.7. Treatment -Emergent Adverse Events  
TEAE are defined as AEs that begin or worsen after the first dose of study drug administration, 
as defined in the SAP. 
12.2. Serious Adverse Events  
12.2.1. Definition of Serious Adverse Event  
An SAE is defined as any AE occurring at any dose that results in any of the following outcomes:  
‚Ä¢ Results in death  
‚Ä¢ Is life threatening  
‚Ä¢ Requires inpatient hospi[INVESTIGATOR_1081]  
‚Ä¢ Results in persistent or significant disability/incapacity, or substantial disruption of 
the ability to conduct normal life functions 
‚Ä¢ Is a congenital anomaly/birth defect  
‚Ä¢ An important medical event 
NOTE:  An emergency room visit without hospi[INVESTIGATOR_282607] , nor does hospi[INVESTIGATOR_282608].  However, unexpected complications and/or prolongation of hospi[INVESTIGATOR_282609].  Admission to the hospi[INVESTIGATOR_180136] (eg, no place to stay, live too far away to come for hospi[INVESTIGATOR_6042]) will not be considered 
inpatient hospi[INVESTIGATOR_602].  
Important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 55 of 114 Events or Outcomes Not Qualifying as Serious Adverse Events  
The following are not considered SAEs and therefore do not need to be reported as such: 
‚Ä¢ Preplanned or elective hospi[INVESTIGATOR_059] , including social and/or convenience situations 
(eg, due to inclement  weather)  
‚Ä¢ Overdose of either Esperion study drug or concomitant medication unless the event 
meets SAE criteria (eg, hospi[INVESTIGATOR_059]).  However, the event should still be captured 
as a non serious AE on the appropriate eCRF page 
12.2.2. Reporting Serious Adverse Events  
All SAEs occurring from the time of informed consent until 30 days following study completion / 
discontinuation must be reported by [CONTACT_079] [INVESTIGATOR_282610] [ADDRESS_344695] information for the Safety d esignee  will be provided in the SAE 
Completion Guidelines.  
The investigator is required to submit SAE reports to their IRB/IEC in accordance with local 
requirements.  All investigators involved in studies using the same investigational product will 
receiv e any safety alert notifications for onward submission to their local IRB as required.  All 
reports sent to investigators will be blinded. 
All SAEs should be recorded on the eCRF and source documents.  Criteria for documenting the 
relationship to IMP and severity will be the same as those previously described. 
The investigator must continue to follow the patient until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the 
patient dies . 
Within [ADDRESS_344696] update the SAE 
information on the AE eCRF and submit any supporting documentation (eg, patient discharge 
summary or autopsy reports) to designated Safety contact .  
The Sponsor (and/or legally transferred designee) will report SAEs and suspected and 
unexpected serious adverse reactions (S[LOCATION_003]Rs) as required by [CONTACT_282646], 
IECs/IRBs, and/or investigators/institutions in compliance with all reporting requirements 
according to local regulations, laws, and Good Clinical Practice s (GCPs ).  The investigator 
should notify their  IEC/IRB of SAEs occurring at the ir site and other S AE reports received from 
the Sponsor, in accordance with local procedures and statutes.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344697] be reported as an SAE. 
12.2.4. Reports of Pregnancy and Lactation 
Although not considered an SAE (unless an event occurs with a serious outcome), any event of 
pregnancy will be collected by [CONTACT_282647] .  If a female patient should become 
pregnant during the course of the study or within [ADDRESS_344698]  
Muscl
e:  Muscle events have been associated with statins (Thompson 2003)  and other lipid-
lowering therapi[INVESTIGATOR_282611].  Muscle symptoms through AE review, CK elevations, and symptoms of potential myopathy will be closely monitored.  
Hepatic :  Hepatic function will be monitored throughout with the clinical safety labs.  More 
detailed investigation will occur if the safety clinical laboratory results are >3  √ó ULN.  
Neurocognitive Events :  Theoretically, it is possible that lipid -lowering agents that disrupt 
cholesterol homeostasis in the brain could impact neurological function, and there have been 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 57 of 114 reports of cognitive impairment (eg,  memory loss) associated with the use of statin drugs 
(FDA  2012 ).  Summarization of events will occur using prespecif ied Medical Dictionary for 
Regulatory Activities  (MedDRA) terms outlined in the SAP. 
12.4. Data Monitoring Committee  
An independent DMC will monitor unblinded accumulating patient safety and efficacy data until 
the last patient has completed study treatment.  In addition, data on SAEs and deaths, including 
clinical endpoints, will be monitored by [CONTACT_282634].  At each DMC review, 
relevant unblinded safety and efficacy information from ongoing studies of bempedoic acid  will 
be provided to the DMC by [CONTACT_282648].  Additional details will be provided in a DMC Charter. 
12.5. Assessment of Lipid Endpoints  
12.5.1. Lipid Parameters  
After randomization, patients will return to clinic every month.  Clinic al laboratory samples will 
be collected and analyzed for calculated 
LDL -C and lipid and cardiometabolic biomarkers 
including non- HDL -C,  TC, ApoB,  and  at baseline and all clinic visits for 
evaluation of bempedoic acid  effects on lipi[INVESTIGATOR_282612].  
12.5.2. Clinic
al Laboratory Tests (Lipi[INVESTIGATOR_805]) 
Clinical laboratory samples will be collected at all clinic visits.  
Blood draws for lipi[INVESTIGATOR_805] (and glucose) must meet the criteria below.  If these criteria have not been 
met, these blood samples will NOT be collecte d.  If these criteria can be met by [CONTACT_282649] 3  days, these blood samples will be collected at the rescheduled 
clinic visit only.  
‚Ä¢ Blood samples will be drawn after a minimum [ADDRESS_344699] (water is allowed)  
Patients are encouraged to be in a seated position during the blood collection.  Clinical laboratory parameters and tests will include those listed in  Table 4.  Collect ion schedule and instructions are 
provided in the Clinical Laboratory Manual.  A description of the sample collection, storage, and shippi[INVESTIGATOR_282613]  11.1.5. 
When vital signs and laboratory samples are to be collected at the same time point, vital sign measurements will precede laboratory sample collection.  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 58 of 114 Table 4: Clinical Laboratory Parameters (Lipi[INVESTIGATOR_805]) and Cardiometabolic Biomarkers  
Clinical Laboratory Test  Clinical Laboratory Test 
Basic Lipid Parameters  Other Parameters  
‚Ä¢ Total cholesterol (TC)  
‚Ä¢ low-density lipoprotein cholesterol (LDL -C) 
and non- HDL -C 
‚Ä¢ 
‚Ä¢ ‚Ä¢ High -sensitivity C -reactive protein (hs- CRP)  
‚Ä¢ ApoB 
‚Ä¢ 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344700] error, minimum, and maximum. For categorical  variables, the 
frequency and percentage will be given.  
13.2. Determination of Sample Size  
The planned total sample size for this study is 52 with 26 patient s in the bempedoic acid 180 mg 
group and 26 in the placebo group.  This samp le size is expected to  
 
  
13.3. Analysis Populations  
The Full Analysis Set (FAS), used for all of the efficacy analyses, is defined as all randomized 
patients with a baseline lipid value, at least 1 postbaseline lipid value, and having taken their 
study drug within 2 days of the lipid measurement.  The FAS is also known as the modified 
intention -to-treat (mITT) set of patients.  Patients in the FAS will be included in their 
randomized treatment group, regardless of the treatment they actually received.   Other subsets of 
the FAS will be considered to evaluate primary and secondary endpoints as sensitivity analyses and the details will be described in the SAP. 
The Safety Population (SP), used for all of the safety s ummaries, is defined as all randomized 
patients who received at least 1  dose of study medication.  Patients in the SP will be included in 
the treatment group that they actually received, regardless of their randomized treatment .  
13.4. Disposition, Demographics,  and Baseline Characteristics  
Disposition, including reason for withdrawal from the study drug and/or study, will be 
summarized by [CONTACT_1570].   Demographic information and patient characteristics including, 
but not limited to, gender, race, age, and baseline vital signs will also be summarized by 
[CONTACT_1570].  
13.5. Primary Endpoint  
The primary efficacy endpoint is the percent change from baseline to Month 2 in LDL -C.  The 
primary efficacy endpoint will be analyzed using analysis of covariance (ANCOVA), w ith 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344701] (LOCF).  The least squares mean (LSM) and standard error 
(SE) for percent change estimate will be provided for both treatment groups, along with the 
placebo -corrected LSM, its 95% confidence interval (CI) and associated p-value.   
The ANCOVA assumptions will be examined and nonparametric tes t or transformation of the 
data will be considered if these assumptions are not met.  
13.6. Secondary and Exploratory Efficacy Endpoints  
The secondary efficacy endpoints (percent change from baseline to Month 1 in LDL -C; change 
from baseline to Months 1 and 2 in LDL- C; percent change from baseline to Months 1 and  2 in 
ApoB, non- HDL -C,TC, hs- CRP  and ), will be analyzed using the ANCOVA met hod 
similar to the primary endpoint.   Baseline value for TC, non- HDL -C, w
ill 
be the average of S4 and Day 1 values; ApoB and hs- CRP  will be the Day 1 value, if only 
1 value is available, the single value will be used as the baseline.  Each ANCOVA will be 
performed using the FAS, with patients included in their randomized treatment group regardless of the treatment they actually received.  Missing values will be imputed using LOCF , where 
applicable.  For each parameter and analysis time point, the LSM and SE will be provided for both treatment groups, along with the placebo-corrected LSM, its 95% CI and associated p value. 
All e
fficacy endpoints will be analyzed at a significance level of 0.05, no multiplicity adjustment 
will be implemented.  
Exploratory endpoints will be summarized by [CONTACT_9086].  
13.7. Safety Endpoints  
The safety analyses for this study will be descriptive in nature, no statistical inferences are 
planned 
The subject incidence of all TEAE, SAEs, related AE s, AEs leading to withdrawal of study drug 
and/or study, fatal AEs, and AESI will be tabulated by [CONTACT_9313] (SOC) and preferred 
term in descending order of frequency and by [CONTACT_1570].  Clinical safety laboratories, including hematology, blood chemistry, HbA
1C, glucose, and 
urinalysis; PE findings; vital signs; and weight will be summarized by [CONTACT_282650] (where appropriate) at each postbaseline time point. 
Hepatic Safety  
For liver- associated enzymes and TB, the number and percent of patients with abnormal values 
for ALT, AST, and TB will be summarized.  All liver- associated laboratory abnormalities will be 
assessed for Hy‚Äôs Law criteria (‚â•3  √ó ULN for either ALT or AST, with accompanying TB >2  √ó 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344702] in the absence of other known causes) will also be applied to the data; any potential Hy‚Äôs 
law cases will be listed separately.  
Musculoskeletal Safety  
AEs of muscle-related symptoms will be summarized by [CONTACT_1570].  In addition, the number and pe rcent of patients with abnormal CK values will be summarized.  Finally, muscle-
related AEs will be summarized by [CONTACT_282622].  
Diabetes/Hyperglycemia  
Cases of new onset of diabetes will be recorded as AEs and will be summar ized using the 
appropriate SOC.  These events will be summarized by [CONTACT_282651]. 
Renal Safety  
Baseline eGFR and values of CK will be summarized by [CONTACT_282624].  Shift tables of eGFR category from baseline over the study, will be provided by 
[CONTACT_3227].  
Neurocognitive Events  
Neurocognitive events will be identified and evaluated by [CONTACT_282652].  Summarization of neurocognitive events will occur using prespecified 
MedDRA terms and will be performed by [CONTACT_1570] . 
13.8. Pharmacokinetic s 
Three t rough plasma concentrations of bempedoic acid  and ESP15228 will be collected and 
summarized from patients at predose (T1), T2, and T3 for use in further developi[INVESTIGATOR_282614]. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344703] ACCESS TO SOURCE DATA/DOCUMENTS  
14.1. Study Monitoring  
The Sponsor (or its authorized representative) has the obligation to follow this study closely to 
ensure that the study is conducted in accordance with the protocol, International Conference on Harmonisation (ICH) and GCP guidelines, national and international regulatory requirements, 
and the current Declaration of Helsinki throughout its duration by [CONTACT_76773]‚Äôs facilitie s and other communications.  
These visits will be conducted to evaluate the progress of the study, verify the rights and 
well-being of the patients are protected, and verify the reported clinical study data are accurate, 
complete, and verifiable from source documents.  This includes review of ICDs, results of tests 
performed as a requirement for participation in this study, and any other medical records 
(eg, laboratory reports, clinic notes, study drug dispensing log, pharmacy records, patient sign-in 
sheet s, patient-completed questionnaires, telephone logs) required to confirm information 
contained in the eCRFs. 
A monitoring visit should include a review of the essential clinical study documents (regulatory 
documents, case report forms, medical records and source documents, drug disposition records, patient informed consent forms, etc) as well as discussion on the conduct of the study with the 
Investigator and staff. 
The monitor should conduct these visits as frequently as appropriate for the clinical study.  T he 
Investigator and staff should be available during these visits for discussion of the conduct of the 
study as well as to facilitate the review of the clinical study records and resolve/document any 
discrepancies found during the visit.  
All monitoring activities will be reported and archived.  In addition, monitoring visits will be 
documented at the clinical site by [CONTACT_76775] -specific monitoring log. 
14.2. Audits and Inspections  
Representatives of the Sponsor or its author ized clinical quality assurance group may visit a 
clinical site at any time during the study to conduct an audit of the study in compliance with 
regulatory guidelines and company policy.  These audits will require access to all study records, including source documents, for inspection and comparison with the eCRFs.  Patient privacy 
must be respected.  The Investigator and clinical site personnel are responsible for being present 
and available for consultation during routinely scheduled site audit visits conducted by [CONTACT_282653].  
The clinical study may also be inspected by [CONTACT_282654] (or other regulatory authority) to 
verify that the study was conducted in accordance with protocol requirements, as well as the applicable r egulations and guidelines. 
In the event the Investigator is contact[CONTACT_282655], the Investigator will promptly notify the Sponsor of all such requests and will promptly forward a copy of all such inspection reports. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 63 of 114 15. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with GCP and all applicable regulatory requirements, the Sponsor / 
designee may conduct a quality assurance audit.  Please see Section  14.[ADDRESS_344704]/Independent Ethics Committee Approval  
Before initiation of the study, the Investigator must o btain approval or favorable opi[INVESTIGATOR_180140], ICD, and any material related to patient recruitment from an IRB or IEC.  For 
locations participating within the US, the IRB must comply with the provisions specified in 
21 Code of Federal Regul ations ( CFR ) Part  56, ICH and GCP guidelines, and applicable 
pertinent state and federal requirements.  For locations participating outside of the US, the IRB 
or IEC must comply with the applicable requirements of each participating location, including 
ICH and GCP guidelines, except where a waiver is applicable. 
IRBs and IECs must be constituted according to the applicable laws.  It is the responsibility of 
each clinical site to submit the protocol, IB, patient informed consent, patient recruitment material s (if applicable), and other documentation as required by [CONTACT_282656].  A copy of the written approval must be provided to the Sponsor.  
The documentation should clearly mention the approval/favorable opi[INVESTIGATOR_29925], the 
patient informed consent form, and patient recruitment materials (if applicable), including 
respective version dates.  The written approval and a list of the voting members, their titles or 
occupations, and their institutional affiliations must be obtained from the IRBs or IECs and 
provided to the Sponsor prior to the release of clinical study supplies to the clinical site and 
commencement of the study.  If any member of the IRB or IEC has direct participation in this 
study, written notification regarding his or her abstinence from voting must also be obtained. 
Clinical sites must adhere to all requirements stipulated by [CONTACT_1765].  This 
includes notification to the IRB or IEC regarding: protocol amendments, updates to the ICD, recruitment  materials intended for viewing by [CONTACT_1962], aggregate safety reports required by 
[CONTACT_282657], serious and unexpected AEs, reports and updates regarding the ongoing review of the study at intervals specified by [CONTACT_282658] C, and submission 
of final study reports and summaries to the IRB or IEC. 
It is the responsibility of each clinical site to submit information to the appropriate IRB or EC for 
annual review and annual re-approval. 
The Investigator must promptly inform thei r IRB or IEC of all SAEs or other safety information 
reported from the patient or the Sponsor. 
16.2. Ethical Conduct of the Study  
The investigator agrees, when signing the protocol, to conduct the study in accordance with 
ethical principles that have their origin in the current revision of the Declaration of Helsinki and 
are consistent with ICH/GCP, applicable regulatory requirements, and policies and procedures as outlined by [CONTACT_282659]. 
The Investigator agrees to all ow monitoring and auditing of all essential clinical study 
documents by [CONTACT_282660], EMA, or 
other appropriate regulatory authorities.  Monitoring and auditing visits by [CONTACT_282661], Inc. 
Clinical Study Protocol 1002-[ADDRESS_344705] sign and return to the Sponsor 
the ‚ÄúI nvestigator‚Äôs Signature‚Äù page (see  Appendix 3)  and provide a copy of current curriculum 
vitae.  For this study and all studies conducted under an IND, the Investigator must sign and 
return a completed Form FDA  1572 ‚ÄúStatement of Investigator‚Äù to the Sponsor (or designee).  
For European Union (EU) investigators, equivalent information contained within the FDA 1572 form may be requested unless a waiver has been requested and received by [CONTACT_282662].  
16.3. Written Informed Consent  
The Principal Investigator(s) at each center will ensure that the patient is given full and adequate 
oral and written information about the nature, purpose, possible risk and benefit of the study.  
Patients must also be notified that they are free to discontinue from the study at any time.  The patient should be given the opportunity to ask questions and allowed time to consider the 
information provided. 
The patient‚Äôs signed and dated informed consent must be obtained before conducting any study 
procedures. 
The Principal Investigator(s) must maintain the original, signed ICD.  A copy of the signed ICD 
must be given to the patient. 
16.4. Patient Confidentiality  
The names and identities of all research patients will be kept in strict confidence and will not 
appear on eCRFs or other records provided to or retained by [CONTACT_1034] (or the Sponsor‚Äôs authorized representative).  If a patient‚Äôs name [CONTACT_76797], it must be redacted and 
replaced with the patient identifier before a copy of the document is supplied to the Sponsor or Sponsor‚Äôs authorized representative.  The ICD must include appropriate statements explaining that patient data will be confidential and what actions will be taken to ensure patient 
confidentiality.  
Any other confidentiality requirements specified by [CONTACT_779], IRB or IEC, or national or local 
regulations will be adhered to and detailed appropriately in the ICD. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 66 of 114 17. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  
17.1. Inspection of Records  
Applicable regulations require the Sponsor (or the Sponsor‚Äôs authorized repr esentative) to 
inspect all documents and records to be maintained by [CONTACT_737], including but not limited 
to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the patients in this study.  These regulations 
also allow the Sponsor‚Äôs records to be inspected by [CONTACT_199873].  The Investigator will permit study -related monitoring, audits, IRB or IEC review, and 
regulatory inspections by [CONTACT_20618]/documents.  Direct access 
includes permission to examine, analyze, verify, and reproduce any records and reports that are 
important to the evaluation of a clinical study.  
17.2. Retention of Records 
In compliance with the ICH/GCP guidelines, the Investigator/Institution agrees to retain and maintain all study records that support the data collected from each patient, as well as all study documents as specified in ICH/GCP, Section [ADDRESS_344706] be contact[CONTACT_180219].  Under no circumstances shall the 
Investigator relocate or dispose of any study documents before having obtained written approval 
from the Sponsor. 
Essential records (including eCRFs, source documents, study drug disposition records, signed 
patient ICDs, AE reports, and other regulatory documents) as required by [CONTACT_1729], must be maintained for 2 years after a marketing application is approved for the drug 
for the indication for which it is being investigated; or, if no application is to be filed or if the 
application is not approved for such indication, until [ADDRESS_344707]. 
It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these 
documents no longer need to be retained. 
17.3. Case Report Forms and Study Records  
Access to eCRFs will be provided to the clinical site. As part of the responsibilities assumed by [CONTACT_6231], the Investigator agrees to maintain adequate case histories for the patients treated as part of the research under this protocol.   The Investigator agrees to maintain 
accurate source documentation and eCRFs as part of the case histories.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 67 of 114 Study records are comprised of source documents, eCRFs, and all other administrative 
documents (eg, IRB or IEC correspondence, clinical study materials and supplies shipment 
manifests, monitoring logs, and correspondence).  A study -specific binder will be provided with 
instructions for the maintenance of study records. 
Source docum entation is  defined as any hand written or computer-generated document that 
contains medical information or test results that have been collected for or in support of the 
protocol specifications (eg, laboratory reports, clinic notes, study drug disposition log, pharma cy 
records, patient sign -in sheets, patient completed questionnaires, telephone logs, and x- rays).  All 
draft, preliminary, and pre/final iterations of a final report are also considered to be source documents (eg, faxed and hard copy of laboratory reports, faxed and hard copy of initial results, and final report).  
The Investigator agrees to allow direct access to all essential clinical study documents for the 
purpose of monitoring and/or auditing by [CONTACT_282663]. 
Data reflecting the patient‚Äôs participation with the study drug under investigation are to be 
reported to the Sponsor.  The data are to be recorded on the eCRFs and/or other media provided or approved by [CONTACT_1034].  
A completed eCRF must be submitted for each patient who receives study drug, regardless of 
duration.  All supportive documentation submitted with the eCRF, such as laboratory or hospi[INVESTIGATOR_1097], should be clearly identified with the study and patient number.  Any personal 
information, including patient name, should be removed or rendered illegible to preserve 
individual confidentiality.  The eCRF should not be used as a source document unless otherwise specified by [CONTACT_1034].  
Neither the Sponsor nor a service provider contracted to analyze data and complete the study 
report is permitted to interpret a blank answer; therefore, all fields should be completed.  All requested information must be entered on the eCRFs. If an item is not available or is not 
applicable, this fact should be indicated as not available (N/A) or not done (N/D); do not leave a 
field blank.  
Each set of completed eCRFs must be signed and dated by [CONTACT_282664].  The completed database is to be returned to 
the Sponsor as soon as practical after completion by [CONTACT_76787]. 
It is essential that all dates appearing on the Sponsor‚Äôs patient data collection forms for 
laboratory tests, cultures, etc, be the dates on which the specimens were obtained or the 
procedures performed.  The eCRFs will be electronically signed by [CONTACT_282665].  All data collection forms should be completed 
within a timely manner according to the eCRF completion guidelines following the evaluation . 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344708] agree to the responsibilities and obligations listed below, as specified by 
[CONTACT_282666]/EMA regulatory requirements or ICH/GCP guidelines: 
‚Ä¢ Agree to conduct the study in accordance with the relevant current protocol 
‚Ä¢ Agree to p ersonally conduct or supervise the described investigation(s) 
‚Ä¢ Agree to inform any patients, or persons used as controls, that the study drugs are 
being used for investigational purposes and ensure that the requirements relating to 
obtaining informed consent and IRB/IEC review and approval are met  
‚Ä¢ Agree to report adv erse experiences that occur during the course of the 
investigation(s)  
‚Ä¢ Read and understand the information in the IB, including the potential risks and side effects of the study drug  
‚Ä¢ Ensure that all associates, colleagues, and employees assisting in the co nduct of the 
study are informed about their obligations in meeting the above commitments 
‚Ä¢ Maintain adequate and accurate records and make those records available for 
inspection  
‚Ä¢ Ensure that an appropriate IRB/IEC will be responsible for the initial and continuing review and approval of the clinical investigation 
‚Ä¢ Agree to promptly report to the IRB/IEC all changes in the research activity and all unanticipated problems involving risks to patients or others 
‚Ä¢ Agree to not make changes in the research without IRB /IEC approval, except where 
necessary to eliminate apparent hazards to patients  
‚Ä¢ Comply with all other requirements regarding the obligations of clinical Investigators 
and all other pertinent requirements. 
‚Ä¢ Refer also to:  
‚àí FDA Regulations Related to GCP and C linical Trials: 
http://www.fda.gov/oc/gcp/regulations.html 
‚àí Guidance and Information Sheets on GCP in FDA- Regulated Clinical Trials: 
http://www.fda.gov/oc/gcp/guidance.html 
‚àí Guidance for IRBs and Clinical Investigators: 
http://www.fda.gov/oc/ohrt/irbs/default.htm 
‚àí DIRECTIVE 2001/20/EC:  http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 69 of 114 ‚àí Guidance for Industry ‚Äì E6 Good Clinical Practice: Consolidated Guidance: 
http://www.fda.gov/cder/guidance/959fnl.pdf 
18.2. Amendments  
Changes to the rese arch covered by [CONTACT_282667].  All amendments to the protocol must be initiated by [CONTACT_282668].  Protocol amendments must not be implemented without prior IRB or IEC approval.  Documentation of amendment approval by [CONTACT_282669].  When the change(s) involve only logistic or administrative aspects of the study, the IRB or IEC only needs to be notified.  
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the Investigator will contact [CONTACT_1689].  Except in emergency situations, this contact 
[CONTACT_41042].  In all cases, contact [CONTACT_282670].  The data recorded on the eCRF and source documents will reflect 
any departure from the protocol and the source documents will describe the departure and the 
circumstances requiring it.  
18.3. Financial Disclosure  
Prior to the start of the study, Investigators will release sufficient and accurate financial information that permits the Sponsor to demonstrate that an Investigator and all study relevant 
assigned personnel have no personal or professional financial incentive regarding the future 
approval or disapproval of the study drug such that his or her research might be biased by [CONTACT_282671]. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 70 of 114 19. PUBLICATION AND DISCLOSURE POLICY  
It is understood by [CONTACT_76791]‚Äôs staff and associates as may be necessary to conduct 
this clinical study.  
All information derived from this clinical study will be used by [CONTACT_1034] (or designee) and 
therefore, may be disclosed by [CONTACT_1034] (or designee) as required to other clinical 
Investigators, to the FDA, EMA, and to other government agencies, or in connection with intellectual property filings or publications.  In order to allow for the use of the information 
derived from this clinical study, it is understood by [CONTACT_282672].  The 
Investigator agrees to maintain this information in confidence, to use the information only to 
conduct the study, and to use the information for no other purpose without the Sponsor‚Äôs prior 
written consent ( or as otherwise may be permitted pursuant to a written agreement with the 
Sponsor or its designee). 
The results of the study will be reported in a clinical study report prepared by [CONTACT_1034] (or 
designee), which will contain eCRF data from all clinical s ites that conducted the study. 
The Sponsor shall have the right to publish data from the study without approval from the 
Investigator.  Manuscript(s) and abstract(s) may only be prepared through cooperation between 
the Sponsor (or designee) and the study Investigator(s).  If an Investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the Spons or for review 
in accordance with the provisions of such Investigator‚Äôs written agreement with the Sponsor (or designee) before submission for publication or presentation.  If requested by [CONTACT_39974], the Investigator will withhold such publication in accordance with the provisions of such 
agreement.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344709] OF REFERENCES 
Food and Drug Administration (2012). FDA announces safety changes in labeling for some 
cholesterol -lowering drugs [Press release]. Retrieved from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm  
Jacobson TA for the NLA Task Force on Statin Safety - 2014 update. J Clin Lipi[INVESTIGATOR_37487]. 
2014;8:S1-4.  Mozffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al, for the writing 
group Members. Heart Disease an d Stroke Statistics ‚Äî2015 Update. A Report from the 
American Heart Association. Circ. 2015;131:e29-322. 
Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: 
epi[INVESTIGATOR_282615]. Eur Heart J. 2014; 35:2950-9. 
Sharrett AR,  Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Atherosclerosis 
Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein 
cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL dens ity 
subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-13. 
Stone NJ, Robinson J, Lichtenstein AH, Bairey Merc CN, Blum CB, Eckel RH, et al. 
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce a therosclerotic 
cardiovascular risk in adults: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129([ADDRESS_344710] 2):S1 -45. 
doi: 10.1161/01.cir.[PHONE_5875].[ZIP_CODE].7a 
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003:289:1681-90. World Health Organization (WHO) Fact Sheet No 317 Updated January 2015. 
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 72 of 114 21. APPENDICES  
Appendix 1: Schedule of Events (Subject Visit Schedule) 
Appendix 2: Sponsor‚Äôs Signature 
[CONTACT_76798] 3: Investigator‚Äôs Signature  
[CONTACT_76798] 4: Summary  of Changes in Amendment 1 
   
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 73 of 114 APPENDIX 1. SCHEDULE OF EVENTS (SUBJECT VISIT SCHEDU LE) 
 Schedule of Events  
Visit  S11,2 S2 S3 S4 T1 T2 T3/EOS)3 
Month  Month -4.5 Month -3 Month -2 Month -1 Week  0 Month 1 Month 2 
Day 
Procedure  Day -135 Day-90 ¬±3 Day -60 ¬±3 Day -30 ¬±3 Day 
1* Day31 ¬±3  Day61 ¬±3  
Informed Consent  X       
Enrollment Criteria X X X X    
Demographics  X       
Medical History  X       
Concomitant Medications  X X X X X X X 
Adverse Event Recording   X X X X X X 
Physical Exam  X     X 
Weight4 X    X  X 
Height  X       
Vital Signs6 X X X X X X X 
Serology7 X       
Serum Pregnancy/FSH8  X       
Urine pregnancy test for 
women of childbearing potential only      X   
TSH  X       
Clinical Safety Labs9 X    X X X 
Basic Fasting Lipi[INVESTIGATOR_805]10 X X** X X*** X X X 
ApoB and hs- CRP   X   X X X 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 74 of 114  Schedule of Events  
Visit  S11,2 S2 S3 S4 T1 T2 T3/EOS)3 
Month  Month -4.5 Month -3 Month -2 Month -1 Week  0 Month 1 Month 2 
Day 
Procedure  Day -135 Day-90 ¬±3 Day -60 ¬±3 Day -30 ¬±3 Day 
1* Day31 ¬±3  Day61 ¬±3  
HbA 1C X    X  X 
PK ‚Äì predose trough     X X X 
Diet and exercise counseling11 X X   X X X 
Establish Patient Eligibility      X   
Randomization     X   
IWRS Contact12 X    X X X 
PCSK9i administered at site   X X X X X  
Double-blind Drug Dispensing     X X  
IMP Return/Compliance       X X 
PCSK9i Return/Accountability   X X X X X  
NOTE: For patients who withdraw from study drug treatment, but consent to be followed for safety assessments and return to cl inic for these visit, the visits will occur according 
to the protocol schedule.  Safety assessments should include clinical safety and basic lipid laboratories, adverse events (AEs), physical examination (PE), and vital signs.  For 
patients who withdraw from study drug treatment, but consent to be followed for safety assessments by [CONTACT_648], the telephone contacts will occur according th e protocol schedule 
with information regarding current health status and to collect information on AEs (eg, recent procedures, hospi[INVESTIGATOR_602], and if the patient has died, the cause of death).  If a 
patient does not provide consent to be followed for safety assessments per the protocol (either by [CONTACT_282673]), Visit  T4 will be considered the End of Study 
(EOS)/Early Withdrawal from study and no further visits will be scheduled.  
[ADDRESS_344711] prior to the next witnessed PCSK9i dose if patient fails to meet  lipid entry criterion at 
Visit S1.  If this optional basic fasting lipid is completed, the average of the 2 lipid value s will be used to determine eligibility.  
2 A recheck of blood pressure may be completed prior to T1 if the patient‚Äôs diastolic blood pressure ( DBP ) and/or systolic blood pressure ( SBP) meet the exclusion criteria levels.  
Patients may randomize after blood pressure medications have been adjusted, the patients have been on stable doses of blood pressure medications for at least 2 weeks, and the 
repeat blood pressure values (DBP and/or SBP) do not meet exclusionary values.  Repeat labs may be completed prior to T1 to determine eligibility if the patie nt‚Äôs estimated 
glomerular filtration rate (eGFR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) or other labs meet exclus ion criteria levels.  If this optional lab is 
completed, the repeated value will be used to determine eligibility.  
3 All procedures will be completed for all patients at either T3/EOS if completing the study or early withdrawal.  
4 Body weight will be measured while fasting, using consistent scales, after voiding, and without shoes and outerwear (eg, coats).   
6 Vital signs will include DBP, SBP, heart rate (HR) and will be collected prior to any blood sample collection.  Patient will rest for [ADDRESS_344712] completed in women of child -bearing age only. FSH in naturally postmenopausal women ‚â•1 year without menses and <55 years;  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 75 of 114 9 Clinical safety labs include hematology, blood chemistry, and urinalysis at all visits.  Please refer to laboratory manual fo r detailed schedule of tests.  
10 Basic fasting lipi[INVESTIGATOR_282616] (TC), calculated low -density lipoprotein cholesterol (LDL -C),  non-HDL -C,), and 
).   
11 Diet and exercise counseling per local and/or regional guidelines for the management of hyperlipi[INVESTIGATOR_035].  
12 Interactive web response system (IWRS) contact [CONTACT_282674] n visit date.  
* Patients must be on PCSK9 for 30 ¬± 3 days during each month of the PCSK9 run -in period before initiating Day  1.   
** LDL-C must be ‚â•160 mg/dL  and TG <500 mg/d L before initiating PCSK9i.  A local lab may be used to assess LDL -C and TG  for eligibility prior to initiating Repatha, but a 
central lab must also be conducted at this visit.  
*** LDL-C must be ‚â• 70 mg/dL to qualify for randomization.  Only a central lab may be used to assess entry LDL -C. 

Bempedoic Acid Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039 Amendment 1, 05 March 2017 
APPENDIX 2. SPONSOR'S SIGNATURE 
[CONTACT_2759]: A Randomized, Double-Blind, Parallel Group, Multicenter Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg 
QD when added to PCSK9-Inhibitor Therapy 
Study Number: 1002-039 
Final Date: [ADDRESS_344713] to critical review and has been approved by [CONTACT_1034]. 
The following personnel contributed to writing and/or approving this protocol: 
Signed: -
Confidential Page 76 of 114 

Bempedoic Acid Esperion Therapeutics, Inc. 
Clinical Study Protocol I 002-039 Amendment 1, 05 March 2017 
Study Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg 
QD when added to PCSK9-Inhibitor Therapy 
Study Number: 1002-039 
Final Date: [ADDRESS_344714] to critical review and has been approved by [CONTACT_1034]. 
The following personnel contributed to writing and/or approving this protocol: 
Signed:-------
Confidential Page 77 of 114 Date: 9-March-2017 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 78 of 114 APPENDIX 3. INVESTIGATOR‚ÄôS SIGNA TURE  
Study Title:  A Randomized, Double-Blind, Parallel Group, Multicenter Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid (ETC -1002) 180 mg 
QD when added to PCSK9-Inhibitor Therapy  
Study Number:  1002-039 
Final Date: [ADDRESS_344715] the study as described in the protocol.  
 
 
Signed:   Date:   
 Name [CONTACT_2760]:  
Title:  
Affiliation:  
Address:  
Phone Number:    
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 79 of 114 APPENDIX 4. SUMMARY OF CHANGES IN AMENDMENT 1  
SUMMARY OF CHANGES 
CLINICAL STUDY PROTO COL  
Study Number:  1002-039 
Study Title:  A Randomized, Double-Blind, Parallel Group, 
Multicenter Study to Evaluate the Efficacy and Safety of 
Bempedoic Acid (ETC -1002) 180 mg QD When added to 
proprotein convertase subtilisin/kexin type 9 
(PCSK9) -inhibitor Therapy 
Protocol Version Incorporating 
Current Summary of Changes:  Amendment 1, 05 March  2017 
Preceding Protocol Version:  Original Protocol, [ADDRESS_344716] Name: [CONTACT_76753] -1002 
Conventions used in this Summary of  Changes Document  
1. The text immediately preceding and following a change to the protocol is included for 
each change in order to provide the reviewer with a reference point to identify the change 
in the protocol. 
2. All locations (ie, section numbers and/or header text) refer to the current protocol 
version, which incorporates the items specified in this Summary of Changes document. 
3. The original text is from the preceding protocol version. 
4. In the ‚ÄúNew Text‚Äù, all substantive text added to the protocol is bolded and italicized.  
5. In the ‚ÄúNew Text‚Äù, text deleted from the protocol is indicated in strikethrough font. 
Summary and Justification of Changes 
Below are the main protocol changes:  
‚Ä¢ The PCSK9 run-in was extended from 1 month to 3 months in order to ensure all 
patients reach steady state prior to randomization.  
‚Ä¢ Added/revised the following subject exclusion criteria to exclude patients that were 
recently on PCSK9 inhibitors as well as HeFH patients (this population will be 
studied in P3 trials):  
‚àí Heterozygous Famil ial Hypercholesterolemia (HeFH)  
‚àí Concomitant use of a PCSK9 inhibitor (Praluent¬Æ [alirocumab] or Repatha¬Æ 
[evolocumab]) at (Visit S1) or prior use within the past 16 weeks of Visit  S1 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 80 of 114 ‚àí Use of any experimental or investigational drugs within 30  days or 5 half- lives, 
whichever is longer  
‚Ä¢ Updated contraception language to align with other P3 ETC- 1002 clinical trials.   
‚àí Added requirement that women use 2 rather than  1 form of acceptable 
contraception; expanded definition of true abstinence. 
‚Ä¢ Removed remnant ECG language.  There are no ECG assessments, these were 
inadvertently added to the original protocol  
‚Ä¢ Removed evaluation of PCSK9  levels from exploratory objectives and endpoints 
‚Ä¢ Specified that LDL -C levels used for evaluation for study inclusion c an use a local 
lab at S3, but that S4 evaluation can only use a central lab 
 
CHANGE 1  REVISION OF PROTOCOL TITLE AND TITLE PAGE VERSION 
INFORMATION 
Location: 
Protocol title  
Original Text:  
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and 
Safety of Bempedoic Acid (ETC -1002) 180 mg QD when added to PCSK9-Inhibitor Therapy 
New Text:  
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC -1002) 180 mg QD  when added to Proprotein C onvertase 
Subtilisin/K exin Type 9 ( PCSK9 )-Inhibitor Therapy 
Location: 
Title page  
Original Text:  
 Version  Date   
 Original Protocol:  22 November 2016  
New Text:  
 Version  Date   
 Original Protocol 22 November 2016  
 Protocol Amendment 1:  05 March 2017  
 
%HPSHGRLF$FLG (VSHUL RQ7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO  $PHQGPHQW0DUFK
&RQILGHQWLDO 3DJHRI&+$1*( 678'<'(6,*1),*85(5(9,6,216
/RFDWLRQ
6HFWLRQ6\QRSVLVDQG6HF WLRQ2YHUDOO6WXG\'HVLJQ
2ULJLQDO7H[W

1HZ7H[W



Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 82 of 114 CHANGE 3 STUDY OBJECTIVES REVISIONS  
Location: 
Section 2 , Synopsis; 
Section 5.1.3, Exploratory Objectives;  
Section 5.1.6, Exploratory Endpoints 
Original Text:  
N
ew Text:  
 
CHANG
E 4 STUDY METHODOLOGY REVISIONS  
Location: 
Section 2, Synopsis; 
Section 6.1, Overall Study Design 
Original Text:  
This is a Ph ase 2, randomized, double-blind, placebo-controlled, parallel group multicenter study 
that will be conducted at approximately 20 clinical sites in North America.  Screening 
Month -2.5 (Visit S1) will occur approximately 10 weeks prior to randomization.  After 
providing informed consent at Visit S1, patients will stop all background lipid- lowering therapy 
and lipid- modifying nutritional supplements, if applicable.  All patients will return to the clinic 
on W eek -4 (V isit S2).  During this visit, patients w ith an LDL- C value ‚â•160 mg/d L (via central 
or local lab) and triglycerides <500  mg/d L (via central or local lab) will initiate PCSK9 
background therapy (Repatha 420 mg QM).  Sites that do not use a local lab may need to bring 
patients back for another visit to administer PCSK9 background therapy, as a qualifying LDL value is required prior to initiating background therapy.  No other background lipid- modifying 
therapy except study provided PCSK9 will be permitted during the trial.   After a 1-month (at 
least 30 days) PCSK9i lipid- stabilization period, patients will return to the clinic for Visit S3.  
The sole purpose of this visit is to determine entry LDL-C prior to randomization.  Patients with an LDL- C ‚â•70 mg/d L (via central or local lab) at this visit will qualify for randomization.  
Patien ts with LDL -C <70  mg/dL at Visit S3  will be screen failed and no further PCSK9i therapy 
will be administered.  Day 1 should occur immediately (ideally within 3  days) after Visit S3, 
once LDL- C eligibility is established.  On Day  1, qualified patients will be randomized 1:1 to 
bempedoic acid 180 mg/day (n  = 26) or matching placebo (n = 26).  Randomized patients will 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 83 of 114 return for clinic visits at Month 1 (Visit T2) and Month 2 (Visit T3).  Both study drug and 
PCSK9 i doses will be administered on site during clinic visits after all procedures have been 
completed.  
New Text:  
This is a Phase  2, randomized, double-blind, placebo-controlled, parallel group multicenter study 
that will be conducted at approximately 20 clinical sites in North America.  Screening Visit S1 
will occur approximately 2.54.5 months prior to randomization.  After providing informed 
consent at Visit S1, patients will stop all background lipid-lowering therapy and lipid- modifying 
nutritional supplement s, if applicable.  All patients will return to the clinic on Month  -31 
(Visit S2).  During this visit, patients with an LDL-C value ‚â•160 mg/dL (via central or local lab) and triglycerides <500 mg/dL (via central or local lab) will initiate PCSK9i  background therapy 
(Repatha 420 mg once monthly [ QM]).  Sites that do not use a local lab may need to bring 
patients back for another visit to administer PCSK9i  background therapy, as a qualifying LDL- C 
value is required prior to initiating the 3 -month PCSK9i  run-in periodinitial background 
therapy .  No other background lipid- modifying therapy except study -provided PCSK9 i will be 
permitted during the trial.  After a 1 month (at least 30  days ¬±3 days ) PCSK9i lipid stabilization 
period, patients will return to the clinic for Month -2 (Visit S3 ) followed by [CONTACT_43380] -1 (Visit S4 ) 
30 days ¬± 3  days later.  During these visits , Repatha will be administered, labs will be collected , 
and safety assessed. The sole purpose of this At visit S4, is to determine entry  LDL- C will be 
checked a second time prior to randomization.  The sole purpose of this visit is to determine 
entry LDL -C prior to randomization. Patients with an LDL -C ‚â•70 mg/dL (via central or local 
lab) at this visit will qualify for randomization. Patients with LDL -C <70 mg/dL at Visit S 4 will 
be screen failed and no further PCSK9i therapy will be administered.  Day 1 should occur  
immediately (ideally within 3  days)  30 days ¬±3 days  after Visit S 4, once LDL- C eligibility is 
established.  On Day 1, qualified patients will be randomized 1:1 to bempedoic acid 180 mg/day (n = 26) or matching placebo (n = 26).  Randomized patients will return for clinic visits at 
Month 1 (Visit T2) and Month 2 (Visit T3).  Both study drug and PCSK9i doses will be administered on site during c linic visits after all procedures have been completed.  
 
CHANGE [ADDRESS_344717] INCLUSION CRITERIA REVISIONS  
Location: 
Section 2, Synopsis; 
Section 7.1, Subject Inclusion Criteria 
Original Text:  
1. Provision of written informed consent must be obtained prior to any study- specific 
procedure. 
2. Age ‚â•18 years or legal age of majority depending on regional law, whichever is greater at 
Month -2.5 (Visit S1) 
3. Fasting, calculated LDL -C at screening (Month -1) ‚â•160 mg/dL and ‚â•70 mg/dL at 
Visit S3  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 84 of 114 Note:  A single repeat of LDL -C may be completed.  For those patients who have a repeat 
LDL-C, the average of the [ADDRESS_344718] be: 
a. Naturally postmenopausal defined as ‚â•1 year without menses and:  
‚àí  ‚â•55 years, or  
‚àí  <55 years with follicle -stimulating hormone (FSH) ‚â•40.0 IU/L; or 
b. Surgically  sterile including hysterectomy, bilateral oophorectomy, and/or tubal 
ligation; or 
c. Women of childbearing potential willing to use 1  acceptable method of birth control 
including: ‚àí oral, implanted, topi[INVESTIGATOR_282597]  
‚àí placement  of an intrauterine device with or without hormones 
‚àí barrier  methods including condom or occlusive cap with spermicidal foam or 
spermicidal jelly  
‚àí vasectomized male partner who is the sole partner for this patient  
‚àí true abstinence (not including periodic abstinence such as calendar, ovulation, 
symptothermal, postovulation methods, or withdrawal) 
There are no protocol- specific birth control requiremen ts for men with partners who are 
able to become pregnant.  
New Text:  
1. Provision of written informed consent must be obtained prior to any study- specific 
procedure. 
2. Age ‚â•18 years or legal age of majority depending on regional law, whichever is greater at 
Month -24.5 (Visit S1) 
3. Fasting, calculated LDL -C at screening (Month -1 Visit S2 ) ‚â•160 mg/dL and ‚â•70 mg/dL 
at Visit S3 S4 
Note:  A single repeat of LDL -C may be completed.  For those patients who have a repeat 
LDL-C, the average of the [ADDRESS_344719] be: 
a. Naturally postmenopausal defined as ‚â•1 year without menses and:  
‚àí  ‚â•55 years, or  
‚àí  <55 years with follicle -stimulating hormone (FSH) ‚â•40.0 IU/L; or 
b. Surgically  sterile including hysterectomy, bilateral oophorectomy, and/or tubal 
ligation; or 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 85 of 114 c. Women of childbearing potential willing to use 12 acceptable method s of birth 
control including: 
‚àí oral, implanted, topi[INVESTIGATOR_282597]  
‚àí placement  of an intrauterine device with or without hormones 
‚àí barrier  methods including condom or occlusive cap with spermicidal foam or 
spermicidal jelly  
‚àí vasectomized male partner who is the sole partner for this patient  
‚àí true abstinence (not including periodic abstinence such as calendar, ovulation, 
symptothermal, postovulation methods, or withdrawal) 
‚àí true abstinence :  when this is in line with the preferred and usual lifestyle of the 
subject.   (Periodic abstinence [eg, calendar, ovulation, symptothermal, 
postovulation methods], declaration of abstinence for the duration of a trial, 
and withdrawal are not acceptable methods of contraception.) (not including 
periodic abstinence such as calendar, ovulation, symptothermal, postovulation 
methods, or withdrawal) 
There are no protocol-specific birth control requirements for men with partners who are 
able to become pregnant.  
 
CHANGE [ADDRESS_344720] EXCLUSION CRITERIA REVISIONS  
Location: 
Section 2, Synopsis; 
Section 7.2, Subject Exclusion Criteria 
Original Text:  
1. Homozygous Familial Hypercholesterolemia (HoFH)  
2. Total fasting TG ‚â•500 mg/dL (5.6 mmol/L ) at Month - 1 (Visit S2) 
Note:  A single repeat of TG may be completed prior to initiation of the single -blind Run-
in period.  For those patients who have a repeat TG, the average of the 2 values will be 
used to determine eligibility.  
3. Renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic 
syndrome, including estimated glomerular filtration rate (eGFR; using central laboratory 
determined Modification of Diet in Renal Disease [MDRD] formula) 
<30 mL/min/1.73 m2 at Month -2.5 (Visit S1) 
Note:  A single repeat of eGFR may be completed prior to randomization.  For those patients who have a repeat eGFR, the average of the 2 values be used to determine 
eligibility.  
4. All patients with known cardiovascular disease (CV D) or peripheral arterial disease 
(PAD) o r cerebrovascular disease (CD)  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 86 of 114 5. History of t ype 1 or t ype 2 diabetes or laboratory evide nce of diabetes (fasting blood 
glucose [ FBG ] >126 mg/d L or glycosylated hemoglobin, Type A 1C (HbA 1C) >6.5%) 
without prior diagnosis of diabetes at Month -2.5 (Visit S1) 
6. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) >160 mmHg 
or diastolic blood pressure (DBP) >100  mmHg at Month  -2.5 (Visit S1) 
7. Uncontrolled hypothyroidism, including thyroid-stimulating hormone (TSH) >1.5 √ó the upper limit of normal (ULN) at Month -2.5 (Visit S1) 
8. Liver disease or dysfunction, including: 
a. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ‚â•2.0  √ó 
ULN at Month -2.5 (Visit  S1).  
b. Positive serology for hepatitis  B surface antigen (HBsAg) and/or hepatitis  C 
antibodies (HCV- ABVivi) at Month -2.5 (Visit S1).  
Note:  If total bilirubin ( TB) ‚â•1.2 √ó ULN, a reflex indirect (unconjugated) bilirubin 
will be obtained and if consistent with Gilbert‚Äôs disease, the patient may be enrolled 
in the study.   
Note: At the discretion of the investigator, a single repeat of ALT and/or AST may be 
completed.  For those patients who have a repeat ALT and/or AST, the average of the 
[ADDRESS_344721] for Hepatitis  C ribonucleic acid (RNA) is negative, patient 
can be enrolled.  
9. Gastrointestinal conditions or procedures (including weight loss surgery; eg, Lap- Band
¬Æ 
or gastric by[CONTACT_6476]) that may affect drug absorption  
10. History  of hematologic or coagulation disorders or a hemoglobin (Hgb) level <10 g/dL at 
Month -2.5 (Visit S1) 
11. History  of malignancy (except non- metastatic basal or squamous cell carcinoma of the 
skin and cervical carcinoma in  situ)  
12. Unexplained  creatine kinase (CK) >3  √ó ULN at screening up to randomization (ie, not 
associated with recent trauma or physically strenuous activity).  Patients with an 
explained CK elevation must have single repeat CK ‚â§3 √ó ULN prior to randomization. 
13. History within the last [ADDRESS_344722] 
been stable, without evidence of abuse prescribed by [CONTACT_76759] a health care 
practitioner can be enrolled after evaluation by [CONTACT_737]. 
14. Blood donation, participation i n a clinical study with multiple blood draws, major trauma, 
blood transfusion, or major surgery with or without blood loss within 30 days prior to randomization 
15. Use of any experimental or investigational drugs within  30 days  
16. Previous enrollment in a n Esper ion Phase 3 bempedoic acid (ETC -1002) clinical study 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 87 of 114 17. Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to 
screening, such as: anacetrapib, dalcetrapib or evacetrapib  
18. Use of, or a plan to initiate, these prohibited therapi[INVESTIGATOR_014]/supplements during the study: 
‚Ä¢ Mipomersen (must be stopped at least 6 months prior to Month -2.5 [Visit S1]),  
‚Ä¢ Lomitapi[INVESTIGATOR_282598] (must be stopped at least 3 months prior to 
Month -2.5 [Visit S1]),  
‚Ä¢ Red yeast rice containing products (must be stopped on or before Month -2.5 [Visit S1]),  
‚Ä¢ Lipid regulating drugs or supplements (must be stopped on or before Month -2.5 [Visit S1])  
19. Planned  initiation or changes to the following drugs prior to Month -2.5: 
‚Ä¢ Hormone replacement (6  weeks prior to Month -2.5) 
‚Ä¢ Thyroid replacement (6  weeks prior to Month -2.5) 
‚Ä¢ Obesity medication (3  months prior to Month -2.5) 
20. A medical or situational (ie, geographical) finding that in the investigator‚Äôs opi[INVESTIGATOR_282603]‚Äôs safety o r ability to complete the study  
21. Patient  is pregnant or breast feeding, or planning to become pregnant dur ing treatment 
and/ or within 12 weeks after the end of treatment  
22. An employee or contractor of the facility conducting the study, or a family member of the 
Principal Investigator, Co-Investigator, or Sponsor. 
New Text:  
1. Homozygous Familial Hypercholesterolemia (HoFH)  
2. Total fasting TG ‚â•500 mg/dL (5.6 mmol/L ) at Month -13 (Visit S2) 
Note:  A single repeat of TG may be completed prior to initiation of the single -blind Run-
in period.  For those patients who have a repeat TG, the average of the 2 values will be 
used to determine eligibility.  
3. Renal dysfunction or a glomerulonephropathy defined as either nephritic or nephrotic 
syndrome, including estimated glomerular filtration rate (eGFR; using central laboratory 
determined Modification of Diet in Renal Disease [MDRD] formula) 
<30 mL/min/1.73 m2 at Month -24.5 (Visit S1) 
Note:  A single re peat of eGFR may be completed prior to randomization.  For those 
patients who have a repeat eGFR, the average of the 2 values be used to determine 
eligibility.  
4. All patients with known cardiovascular disease (CV D) or peripheral arterial disease 
(PAD) o r cerebrovascular disease (CD)  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 88 of 114 5. History of t ype 1 or t ype 2 diabetes or laboratory evide nce of diabetes (fasting blood 
glucose [ FBG ] >126 mg/d L or glycosylated hemoglobin, Type A 1C (HbA 1C) >6.5%) 
without prior diagnosis of diabetes at Month -24.5 (Visit S1) 
6. Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) >160 mmHg 
or diastolic blood pressure (DBP) >100  mmHg at Month -24.5 (Visit S1) 
7. Uncontrolled hypothyroidism, including thyroid- stimulating hormone (TSH) > 1.5 √ó the 
upper limit of normal (ULN) at Month -24.5 (Visit  S1) 
8. Liver disease or dysfunction, including: 
a. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ‚â•2.0  √ó 
ULN at Month -24.5 (Visit  S1).  
b. Positive serology for hepatitis  B surface antigen (HBsAg) and/or hepatitis  C 
antibodies (HCV- ABVivi) at Month -24.5 (Visit S1).  
Note:  If total bilirubin ( TB) ‚â•1.2 √ó ULN, a reflex indirect (unconjugated) bilirubin 
will be obtained and if consistent with Gilbert‚Äôs disease, the patient may be enrolled 
in the study.   
Note: At the discretion of the investigator, a single repeat of ALT and/or AST may be 
completed.  For those patients who have a repeat ALT and/or AST, the average of the 
[ADDRESS_344723] for Hepatitis  C ribonucleic acid (RNA) is negative, patient 
can be enrolled.  
9. Gastrointestinal conditions or procedures (including weight loss surgery; eg, Lap- Band¬Æ 
or gastric by[CONTACT_6476]) that may affect dr ug absorption 
10. History  of hematologic or coagulation disorders or a hemoglobin (Hgb) level <10 g/dL at 
Month -24.5 (Visit S1) 
11. History  of malignancy (except non- metastatic basal or squamous cell carcinoma of the 
skin and cervical carcinoma in  situ)  
12. Unexplained  creatine kinase (CK) >3  √ó ULN at screening up to randomization (ie, not 
associated with recent trauma or physically strenuous activity).  Patients with an 
explained CK elevation must have single repeat CK ‚â§3 √ó ULN prior to randomization. 
13. History within the last [ADDRESS_344724] 
been stable, without evidence of abuse prescribed by [CONTACT_76759] a health care 
practitioner can be enrolled after evaluation by [CONTACT_737]. 
14. Blood donation, participation in a clinical study with multiple blood draws, major trauma, 
blood transfusion, or major surgery with or without blood loss within 30 days prior to 
randomization 
15. Use of any experimental or investigational drugs within  30 days  or 5 half- lives, 
whichever is longer  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 89 of 114 16. Previous enrollment in a n Esperion Phase 3 bempedoic acid ( ETC -1002) clinical study 
17. Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to 
screening, such as: anacetrapib, dalcetrapib or evacetrapib  
18. Use of, or a plan to initiate, these prohibited therapi[INVESTIGATOR_014]/supplements during the study:  
‚Ä¢ Mipomersen (must be stopped at least 6 months prior to Month -24.5 [Visit S1]),  
‚Ä¢ Lomitapi[INVESTIGATOR_282598] (must be stopped at least 3 months prior to 
Month -24.5 [Visit S1]),  
‚Ä¢ Red yeast rice containing products (must be stopped on or before Month -2 4.5 
[Visit S1]),  
‚Ä¢ Lipid regulating drugs or supplements (must be stopped on or before Month -24.5 
[Visit S1])  
19. Planned  initiation or changes to the following drugs prior to Month -24.5: 
‚Ä¢ Hormone replacement (6  weeks prior to Month -2 4.5) 
‚Ä¢ Thyroid repla cement (6  weeks prior to Month -24 .5) 
‚Ä¢ Obesity medication (3  months prior to Month -24.5) 
20. A medical or situational (ie, geographical) finding that in the investigator‚Äôs opi[INVESTIGATOR_282617]‚Äôs safety o r ability to complete the study  
21. Patient  is pregnant or breast feeding, or planning to become pregnant dur ing treatment 
and/ or within 30 days 12 weeks  after the end of treatment  
22. An employee or contractor of the facility conducting the study, or a family member of the 
Principal Investigator, Co-Investigator, or Sponsor. 
23. Heterozygous familial hypercholesterolemia (HeFH)  
24. Concomitant use of a PCSK9 inhibitor (Praluent¬Æ [alirocumab] or Repatha¬Æ 
[evolocumab]) at (Visit S1) or prior use within the past 16 weeks of Visit  S1 
 
CHANGE 7 PCSK9 INHIBITOR ADMINISTRATION CLARIFICATION 
Location: 
Section 2, Synopsis 
Original Text:  
Test product, dose, and mode of administration:   
‚Ä¢ Bempedoic acid 180- mg tablets/day  
‚Ä¢ Matching placebo tablets  
‚Ä¢ PCSK9i ‚Äì Repatha 420 mg QM  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 90 of 114 All study drug (bempedoic acid or placebo) will be ingested once daily with or without food.  On 
clinic days patients will come to the clinic in the fasted state and the PCSK9i and study drug will 
be administered after all study procedures have been conducted. 
New Text:  
Test product, dose, and mode of administration:   
‚Ä¢ Bempedoic acid 180- mg tablets/once per day 
‚Ä¢ Matching placebo tablets /once per day  
‚Ä¢ PCSK9i ‚Äì Repatha 420 mg QMinjection once monthly  
All study drug (bempedoic  acid or placebo) will be ingested once daily with or without food.  On 
clinic days patients will come to the clinic in the fasted state and the PCSK9i and study drug will 
be administered after all study procedures have been conducted.  PCSK9i injections must be 
administered consistently throughout the trial within 30 ¬± 3  days from the previous dose.  
Efficacy will vary if the doses are not consistently administered.  
 
CHANGE 8 REMOVAL OF ECG FROM SAFETY ASSESSMENTS  
Location: 
Section 2, Synopsis.  This change also made as applicable in Sections  1.11, Safety Parameters; 
13.7, Safety Endpoints; 14.1, Safety Monitoring; 17.3, Case Report Forms and Study Records ; 
and Appendix 1 Schedule of Events (Subject Visit Schedule) 
Original Text:  
Adverse events and serious  adverse events ( SAEs ) will be collected and reported.  Other safety 
assessments will include clinical safety laboratories (including hematology, blood chemistry, 
HbA 1C, fasting glucose, and urinalysis), physical examination (PE) findings, vital signs, 
electrocardiogram (ECG) readings, and weight.  
New Text:  
Adverse events and serious adverse events ( SAEs ) will be collected and reported.  Other safety 
assessments will include clinical safety laboratories (including hematology, blood chemistry, 
HbA 1C, fasting glucose, and urinalysis), physical examination (PE) findings, vital signs, 
electrocardiogram (ECG) readings,  and weight. 
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 91 of 114 CHANGE 9 STATISTICAL METHODS REVISIONS  
Location: 
Section 2, Synopsis 
Section 13.2, Determination of Sample Size 
Original Text:  
Sample  Size  
The planned total sample size for this study is 52 with 26 patients in the bempedoic acid 180 mg 
group and in the placebo group.  This sample size  is expected to  
 
  
New Text:  
Sample Size  
The planned total sample size for this study is 52 with 26 patients in the bempedoic acid 180 mg 
group and 26 in the placebo group.  This sample size is expected to  
 
  
 CHANGE 10 REVISIONS TO STATISTICAL METHODS  
Location: 
Section 2, Synopsis 
Section 13.5, Primary Endpoint 
Original Text:  
Primary Endpoint 
The primary efficacy endpoint is the percent change from baseline to Month 2 in LDL -C.  The 
primary efficacy endpoint will be analyzed using analysis of covariance (ANCOVA),  with 
treatment gro up as a factor and baseline LDL -C as a covariate.  Baseline LDL -C is defined as the 
Day [ADDRESS_344725] (LOCF).  The least squares mean (LSM) and standard error (SE) for percent change 
estimate will be provided for both treatment groups, along with the placebo- corrected LSM, its 
95% confidence interval (CI) and associated p -value.  
New Text:  
Primary Endpoint 
The primary efficacy endpoint is the percent change from baseline to Month 2 in LDL -C.  The 
primary efficacy endpoint wi ll be analyzed using analysis of covariance (ANCOVA), with 
treatment gro up as a factor and baseline LDL -C as a covariate.  The details of the ANCOVA 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344726] (LOCF).  The least squares mean (LSM) and standard error 
(SE) for percent change estimate will be provided for both treatment groups, along with the 
placebo -corrected LSM, its 95% confidence interval (CI) and associated p- value.  
Location: 
Section 13.6, Secondary and Exploratory Efficacy Endpoints 
Original Text:  
The secondary efficacy endpoints (percent change  from baseline to Month 1 in LDL -C; change 
from baseline to Months 1 and 2 in LDL- C; percent change from baseline to Months 1 and  2 in 
ApoB, non- HDL -C,TC, hs- CRP and , will be analyzed using the ANCOVA method 
similar to the primary endpoint.  Baseline value for TC, non- HDL -C,  ApoB, and 
hs-CRP  will be Day 1 value.  Each ANCOVA will be performed using the FAS, with patients 
included in their randomized treatment group regardless of the treatment they actually received.  
Missing values will be imputed using LOCF , where applicable.  For each parameter and analysis 
time point, the LSM and SE will be provided for both treatment groups, along with the placebo-
corrected LSM, its 95% CI and associated p value. 
New Text:  
The secondary efficacy endpoints (percent change from baseline to Month 1 in LDL- C; change 
from baseline to Months 1 and 2 in LDL-C; percent change from baseline to Months 1 and 2 in 
ApoB, non- HDL -C,TC, hs -CRP and , will be analyzed using the ANCOVA method 
similar to the primary endpoint.  Baseline value for TC, non- HDL -C,  will be 
the average of S4 and Day 1 values ; ApoB , and hs- CRP  will be the Day 1 value , if only 1 value 
is available, the single value will be used as the baseline.   Each ANCOVA will b e performed 
using the FAS, with patients included in their randomized treatment group regardless of the 
treatment they actually received.  Missing values will be imputed using LOCF, where applicable.  
For each parameter and analysis time point, the LSM and SE will be provided for both treatment 
groups, along with the placebo- corrected LSM, its 95% CI and associated p value.  
 
CHANGE 11  SAFETY ENDOINT REVISIONS  
Location: 
Section 2, Synopsis;  
Section 13.7, Safety  Endpoints 
Original Text:  
Musculoskeletal Safety  
AEs of muscle-related symptoms will be summarized by [CONTACT_1570].  In addition, the 
number and percent of patients with abnormal CK values will be summarized.   

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 93 of 114 Diabetes/Hyperglycemia  
Cases of new onset of diabetes will be recorded as AEs and wi ll be summarized using the 
appropriate SOC.  These events will be summarized by [CONTACT_282675]. 
Renal Safety  
Baseline eGFR and values of CK will be summarized by [CONTACT_282676].  Shift tables of eGFR category from baseline over the study, will be provided by 
[CONTACT_1570].  Finally, muscle -related AEs will be summarized by [CONTACT_282677].  
New Text:  
Musculoskeletal Safety  
AEs of muscle- related symptoms will be summarized by [CONTACT_1570].  In addition, the 
number and percent of patients with abnormal CK values will be summarized.  Finally, muscle -
related AEs will be summarized by [CONTACT_282622]. 
Diabetes/Hypergly cemia  
Cases of new onset of diabetes will be recorded as AEs and will be summarized using the 
appropriate SOC.  These events will be summarized by [CONTACT_282675]. 
Renal Safety  
Baseline eGFR  and values of CK will be summarized by [CONTACT_282624].  Shift tables of eGFR category from baseline over the study, will be provided by 
[CONTACT_1570].  Finally, muscle -related AEs will be summarized by [CONTACT_21747] d by 
[CONTACT_282678].  
 
CHANGE 12  INVESTIGATIONAL PLAN REVISIONS  
Location: 
Section 6.3, Study Duration and Period 
Section 6.4, End of Study 
Original Text:  
6.3  Study Duration and Period 
The duration of treatment will be 18  weeks (2.5-month screening period, a 1- month lipid -
stabilization period, and 2- month treatment period).  
6.[ADDRESS_344727] randomized patient completes the Month 2 visit.  The estimated 
overall duration of the study (first patient first visit [FPFV] to last patient last visit [LPLV]) is 
approximately 8  months. 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 94 of 114 New Text:  
6.3  Study Duration and Period 
The duration of treatment will be 2618 weeks ( 12.5-month screening period, a 31- month lipid -
stabilization period, and 2- month treatment period).  
6.[ADDRESS_344728] randomized patient completes the Month 2 visit.  The estimated 
overall duration of the study (first patient first visit [FPFV] to last patient last visit [LPLV]) is approximately 10.58 months. 
Location: 
Section 6.6.1, Screening and 1 Month PCSK9i Run-in Period 
Original Text:  
Screening will occur approximately 10  weeks prior to Day 1 (Visit T1).  Eligible patients will 
return to the clinical site at Month -1 (Visit S2).  During this visit, patients with an LDL- C value 
‚â•160 mg/d L (via central or local lab) and triglycerides <500  mg/d L (via central or local lab) will 
initiate PCSK9 i background therapy (Repatha 420 mg QM).  No other background lipid-
modifying therapy except study provided PCSK9i will be permitted during the trial.  
New Text:  
Screening will occur approximately 1810 weeks prior to Day 1 (Visit T1).  Eligible patients will 
return to the clinical site at Month -13 (Visit S2).  During this visit, patients with an LDL- C 
value ‚â•160 mg/d L (via central or local lab) and triglycerides <500 mg/d L (via central or local 
lab) will initiate study-provided PCSK9 i background therapy (Repatha 420 mg QM).  No other 
background lipid-modifying therapy except study provided PCSK9i will be permitted during the 
trial.  
Location: 
Section 6.6.2, Randomization and Treatment Period;  
Original Text:  
Patients who satisfy all entry criteria , complete the 2.5-month screening period and 1-month (at 
least 30  days) PCSK9 i run-in period and have an LDL -C ‚â•70 mg/dL at S3 will be randomized.  
Randomization numbers will be assigned via IWRS on Day 1 (Visit T1).  Patients will be 
randomized in a ratio of 1:1 to receive 1 of the following 2 treatments in a double-blind fashion: 
‚Ä¢ Bempedoic acid 180- mg tablet  
‚Ä¢ Matching placebo tablet  
New Text:  
Patients who satisfy all entry criteria , complete the 1.52.5-month screening period and 31-month 
(at least 30  days) PCSK9 i run-in period and have an LDL -C ‚â•70 mg/dL at S 43 will be 
randomized.  Randomization numbers will be assigned via IWRS on Day 1 (Visit T1).  Patients 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 95 of 114 will be randomized in a ratio of 1:1 to receive 1 of the following 2 treatments in a double -blind 
fashion in addition to monthly PCSK9i background therapy : 
‚Ä¢ Bempedoic acid 180- mg tablet  
‚Ä¢ Matching placebo tablet  
 
CHANGE [ADDRESS_344729] REVISION 
Location: 
Section 9.2, A dministration of Investigational Medicinal P roduct  
Original Text:  
PCSK9i will be administered on site at Visits  S2, T1, and T2.  Doses will be stored and 
administered as required in prescribing information  
New Text:  
PCSK9i will be administered on site at Visits  S2, S3, S4, T1, and T2.  Doses will be stored and 
administered as required in prescribing information  
 
CHANGE 14  STUDY PROCEDURES REVISIONS  
Location:  
Section 10.2, Procedures and Schedule of Assessments  
Original Text:  
10.2.1 Screening Month -2.5 (Visit S1) 
The screening period will begin with a screening visit that will occur approximately 10  weeks 
prior to randomization.  Visit S1 will allow the Investigator to assess the patient‚Äôs preliminary 
eligib ility.  After the patient provides written informed consent (see  Section  10.1), the patient 
will undergo the following assessments and procedures at Visit S1: 
‚Ä¢ Demographics 
‚Ä¢ Clinically relevant medical history  
‚Ä¢ Concomitant and prohibited medication review 
‚Ä¢ Height (cm), weight (kg), body mass index (BMI)  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations:  
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚àí ApoB and hs- CRP  
‚àí HbA 1C 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 96 of 114 ‚àí PCSK9i  
‚àí TSH  
‚àí FSH (in appropriate female patients)  
‚àí Serum pregnancy test (on appropriate female patients)  
‚Ä¢ Serology (including HBsAg, Hepatitis  C virus [HCV])  
‚Ä¢ Review of all inclusion/exclusion criteria that can be assessed at this time  
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Contact [CONTACT_282679] (available several days after Visit S1) will be instructed to washout of all lipid -regulating drugs and supplements and to maintain consistent diet and exercise patterns 
throughout the study.  Patients who fail to meet any entry criterion that can be assessed at Visit S1 are considered to be screen failures and are not required to return for additi onal visits 
(although a patient can be seen at any time for safety reasons).  
10.2.2 PCSK9i Run -in Month -1 (Visit S2)  
Prior to scheduling Visit S2, review the screening clinical results to evaluate whether the patient 
continues to meet eligibility criteria . 
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit S2 and proceed with the Visit S2 procedures 
The patient will undergo the following a ssessments and procedures at (Visit  S2) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess A Es (starting from signing of the informed consent document) 
‚Ä¢ Physical  examination (PE)  
‚Ä¢ Vital signs  
‚Ä¢ Basic  fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚Ä¢ ApoB and hs- CRP  
‚Ä¢ PCSK9i   
‚Ä¢ First PCSK9i injection.  Verification of lipid entry criteria (LDL -C value of 
>160 mg/dL and triglycerides <500 mg/dL) must be obtained before starting PCSK9i 
‚Ä¢ Schedule next visit (S3 has to be at least [ADDRESS_344730] dose of PCSK9i ) 
Note:  Local labs can be used to assess LDL -C and TGs for entry.  If using a central lab 
or a local lab with a delay in obtaining results, an optional visit to administer PCSK9i  
may be scheduled.  Patients need to be on Repatha [ADDRESS_344731] 30 days during 
the lipid stabilization period before conducting Visit  S3. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 97 of 114 10.2.3 Screening/Prerandomization (Visit S3)  
One month (30 days) from S2, patients will have their LDL -C evaluation (local or central) prior 
to randomization. 
The patient will undergo the following assessments and procedures at (Visit  S3) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Obtain  fasting LDL -C 
‚Ä¢ Schedule next visit Day  1 (Day  1 should occur immediately [ideally within 3  days] 
after S3, once LDL -C eligibility [‚â•70 mg/dL] is established)  
Note:  Central lab LDL -C results may take up to 3  days to obtain, so please plan 
accordingly if using the central lab .  
10.2.4. Treatment Week 0 (Visit  T1; Day 1) 
Prior to scheduling Visit T1, review S1, S2, and S3clinical results to evaluate whether the patient 
continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit T1 and proceed with 
the Visit T1 procedures 
If the patient has met all inclusion criteria, none of the exclusion criteria, and has been on Repatha [ADDRESS_344732] 
dose.  
The patient will undergo the following assessments and procedures at (Visit T1)  
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Weight  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
Note:  Urine pregnancy test (for females of childbearing potential) 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚àí ApoB and hs- CRP  
‚àí HbA 1C  
‚Ä¢ Predose PCSK9i and PK 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 98 of 114 ‚Ä¢ Review  inclusion/exclusion criteria to establish patient eligibility.  Patient must have 
an LDL -C ‚â•70 mg/dL on S3 before they can be randomized on Day  1. 
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ IWRS contact [CONTACT_282638]-blind study drug 
‚Ä¢ Dispense IMP and provide dosing instructions (two 35-day supply bottles) 
‚àí Subject should be randomized and receive IMP within 3  days of S3, as soon 
as the final LDL- C entry criterion is met  
‚Ä¢ PCSK9i injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit 
10.2.5 Treatment Month 1 (Visit T2 ¬±3 days) 
If the patient is withdrawing early from the study at this visit, proceed to Section  10.3.[ADDRESS_344733] of the required assessments.  
Patients will undergo the following assessments and procedures at Month 1 (Visit T2):  
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs since last visit (ongoing)  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚Ä¢ Predose PCSK9 and PK.  Should be taken ideally within 4 hours of the patient‚Äôs 
normal time of dosing 
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Return of IMP; assessment and recording of IMP compliance 
‚Ä¢ Re-dispense IMP container from Visit T1 to patient for continued dosing and provide 
dosing ins truction  
‚Ä¢ PCSK9 i injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 99 of 114 10.2.6 Treatment Month 2 (Visit T3 ¬±3 days) 
If the patient is withdrawing early from the study at this visit, proceed to  Section 10.3.[ADDRESS_344734] of the required assessments.  
New Text:  
10.2.1. Screening Month -2.5 ‚àí4.5 (Visit S1) 
The screening period will begin with a screening visit that will occur approximately 1018 weeks 
prior to randomization.  Visit S1 will allow the Investigator to assess  the patient‚Äôs preliminary 
eligibility.  After the patient provides written informed consent (see Section  10.1), the  patient 
will undergo the following assessments and procedures at Visit S1: 
‚Ä¢ Demographics 
‚Ä¢ Clinically relevant medical history  
‚Ä¢ Concomitant and prohibited medication review 
‚Ä¢ Height (cm), weight (kg), body mass index (BMI)  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations:  
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , an d )  
‚àí ApoB and hs- CRP  
‚àí HbA 1C 
‚àí PCSK9i  
‚àí TSH  
‚àí FSH (in appropriate female patients)  
‚àí Serum pregnancy test (on appropriate female patients)  
‚Ä¢ Serology (including HBsAg, Hepatitis  C virus [HCV])  
‚Ä¢ Review of all inclusion/exclusion criteria that can be assessed at this time  
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Contact [CONTACT_282680] S 1 central 
clinical laboratory results (available several days after Visit S1) will be instructed to washout of 
all lipid -regulating drugs and supplements and to maintain consistent diet and exercise patterns 
throughout the study.  Patients who fail to meet any entry criterion that can be assessed at 
Visit S1 are considered to be screen failures and are not required to return for additional visits 
(although a patient can be seen at any time for safety reasons).  

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 100 of 114 10.2.2. PCSK9i Run -in Month -13 (Visit S2)  
Prior to scheduling Visit S2, review the screening clinical results to evaluate whether the patient 
continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit S2 and proceed with the 
Visit S2 procedures 
The patien t will undergo the following a ssessments and procedures at (Visit  S2) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Physical examination (PE)  
‚Ä¢ Vital signs  
‚Ä¢ Basic fasting lipi[INVESTIGATOR_805] (TC,  calculated LDL -C, , non- HDL -C, , and ) 
‚Ä¢ ApoB and hs- CRP  
‚Ä¢ PCSK9i  
‚Ä¢ First PCSK9i monthly injection.  Verification of lipid entry criteria (LDL -C value of 
>160 mg/dL and triglycerides <500 mg/dL) must be obtained before starting PCSK9i 
‚Ä¢ Schedule next  visit (S3 has to be at least 30 days ¬±[ADDRESS_344735] dose of 
PCSK9i ) 
‚àí PCSK9i injections must be administered consistently throughout the trial within 
30 ¬± 3 days from the previous dose.  Efficacy will vary if the doses are not 
consistently administered.  
Note:  Local labs can be used to assess LDL -C and TGs for entry.  All other labs must 
be run via the central lab.   If using a central lab or a local lab with a delay in obtaining 
results, an optional visit to administer PCSK9i  may be scheduled.  Patients need to be 
on Repatha [ADDRESS_344736] 30 days ¬±3  days during  the lipid stabilization period 
before conducting Visit  S3. 
10.2.3. PCSK9i Run -in Month -2 Screening/Prerandomization (Visit S3) 
One month (30 days) from S2, patie nts will have their LDL -C evaluation (local or central) prior 
to randomization.Prior to scheduling Visit S3, review the screening clinical results to evaluate 
whether the patient continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit  S3 and proceed with the 
Visit S3 procedures 
The patient will undergo the following assessments and procedures at (Visit S3) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Obtain  Vital signs  
‚Ä¢ Basic fasting  lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non-HDL C, , and ) 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 101 of 114 ‚Ä¢ PCSK9i monthly injection must be given at the end of procedures  
Note:  Central lab LDL -C results may take up to 3  days to obtain, so please plan 
accordingly if using the central lab.  
10.2.4 PCSK9i Run -in Month -1 (Visit S4)  
One month (30 ¬± 3 days) from S 3, patients will have their LDL -C evaluated a second time via 
central lab only  prior to randomization on Day 1. 
The patient will undergo the following assessments and proce dures at (Visit S4) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Vital signs  
‚Ä¢ Basic fas ting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚àí Schedule next visit Day 1 ( Day 1 should occur immediately  30 ¬±3  days after 
S4, once LDL -C eligibility [‚â•70 mg/dL] is established ) 
‚Ä¢ PCSK9i monthly injection  must be given at the end of procedures  
[IP_ADDRESS].2.5. Treatment Week 0 (Visit  T1; Day  1) 
Prior to scheduling Visit T1, review S1, S2, S3 , and S34 clinical results to evaluate whether the 
patient continues to meet eligibility criteria.  
‚Ä¢ If the patient meets eligibility criteria, then schedule the Visit T1 and proceed with 
the Visit T1 pr ocedures  
If the patient has met all inclusion criteria, none of the exclusion criteria, and has been on 
Repatha 420 mg for 30 ¬±[ADDRESS_344737] dose.  
The patient will undergo the following assessments and procedures at (Visit T1 ) 
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs (starting from signing of the informed consent document) 
‚Ä¢ Weight  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Note:  Urine pregnancy test (for fe males of childbearing potential)  
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 102 of 114 ‚àí ApoB and hs- CRP  
‚àí HbA 1C  
‚Ä¢ Predose PCSK9i and PK  
‚Ä¢ Review  inclusion/exclusion criteria to establish patient eligibility.  Patient  must have 
an LDL -C ‚â•70 mg/dL on S3  at S4 before they can be randomized on Day  1. 
‚Ä¢ Conduct diet and exercise counseling  
‚Ä¢ IWRS  contact [CONTACT_282638]-blind study drug 
‚Ä¢ Dispense IMP and provide dosing instructions ( two 35-day supply bottles) 
‚àí Subject should be randomized and receive IMP within 30 ¬± 3 days of S4S3, 
as soon as the final LDL- C entry criterion is met  
‚Ä¢ PCSK9i  injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit  
[IP_ADDRESS].6. Treatment Month 1 (Visit T2 ¬±3 days) 
If the patient is withdrawing early from the study at this visit, proceed to  Section  10.3.[ADDRESS_344738] of the required assessments.  
Patients will undergo the following assessments and procedures at Mont h 1 (Visit T2):  
‚Ä¢ Concomitant and prohibited medication review (ongoing) 
‚Ä¢ Assess AEs since last visit (ongoing)  
‚Ä¢ Vital signs  
‚Ä¢ Clinical laboratory evaluations: 
‚àí Hematology, blood chemistry, and urinalysis 
‚àí Basic fasting lipi[INVESTIGATOR_805] (TC, calculated LDL -C, , non- HDL -C, , and ) 
‚àí ApoB and hs- CRP  
‚Ä¢ Predose PCSK9 and PK .  Should be taken ideally within 4 hours of the patient‚Äôs 
normal time of dosing 
‚Ä¢ Conduct diet and exercise counseling 
‚Ä¢ Return of IMP; assessment and recording of IMP compliance 
‚Ä¢ Re-dispense Dispense  IMP container from Visit T1 to patient for continued dosing 
and provide dosing instructions (35 -day supply bottles)  
‚Ä¢ PCSK9 i injection and IMP must be given at the end of procedures 
‚Ä¢ Schedule next visit 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 103 of 114 [IP_ADDRESS].7 Treatment Month 2 (Visit T3 ¬±3 days) /EOS  
If the patient is withdrawing early from the study at this visit, proceed to Section  10.3.[ADDRESS_344739] of the required assessments.  
 
CHANGE15  ASSESSMENT OF SAFETY REVISION 
Location: 
Section 11.1, Safety Parameters  
Original Text:  
At all clinic visits, investigators will review all safety information including vital signs, AEs, 
concomitant medications, and electrocardiogram ( ECG ) reports and will ensure that the collected 
data are recorded into the appropriate eCRF.  Additionally, c linical laboratory samples will be 
collected and sent for analysis and the investigator will review the results to ensure continued patient safety while participating in the study.  
New Text:  
At all clinic visits, investigators will review all safety infor mation including vital signs, AEs, and 
concomitant medications, and electrocardiogram (ECG) reports  and will ensure that the collected 
data are recorded into the appropriate eCRF.  Additionally, clinical laboratory samples will be 
collected and sent for an alysis and the investigator will review the results to ensure continued 
patient safety while participating in the study.  
 
CHANGE 16  REPORTING ADVERSE EVENTS REVISIONS  
Location: 
Section 12.1.3, Reporting for Adverse Events  
Original Text:  
Clinically significant abnormal laboratory or other examination findings that are detected during 
the study or are present at baseline and significantly worsen during the study should be reported 
as AEs.  The investigator will exercise his or her medical and scientif ic judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically significant.  
Significant abnormal laboratory values occurring during the clinical study will be followed until 
repeat tests return to normal, stabilize, or are no longer clinically significant.  Any abnormal test 
that is determined to be an error does not require reporting as an AE. 
New Text:  
Clinically significant abnormal laboratory or other examination findings that are detected during 
the study or are present at baseline and significantly worsen during the study should be reported as AEs , as described below .  The investigator will exercise his or her medical and scientific 
judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.  Significant abnormal laboratory values occurring during the clinical study will be followed until repeat tests return to normal, stabilize, or are no longer clinically 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-[ADDRESS_344740] that is determin ed to be an error does not require reporting as an 
AE. 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an 
AE only if any one of the following criteria is met:  
‚Ä¢ an action on the study drug is made as a result of the abnormality 
‚Ä¢ intervention for management of the abnormality is required 
‚Ä¢ at the discretion of the investigator should the abnormality be deemed clinically 
significant  
 
CHANGE 17  ELEVATED CK MONITORING REVISION 
Location : 
Section [IP_ADDRESS].3, Monitoring and M anagement of Elevated Creatinine Kinase  
Original Text:  
If at any time after randomization a patient experiences a marked CK elevation >5 √ó ULN, the 
patient will undergo repeat confirmatory assessment as soon as is reasonably possible, preferably 
within 3  to 7 days of the laboratory result becoming available.  
Repeat CK assessment will include query for related symptoms.  
‚Ä¢ If the repeat CK assessment confirms an unexplained (ie, not associated with recent 
trauma or physically strenuous activity) CK abnormality >5 √ó ULN, if asymptomatic the 
investigator with input from the Sponsor may consider continuing study medication with 
continued CK ass essments every 1 -2 weeks.  
New  Text:  
If at any time after randomization a patient experiences a marked CK elevation >5 √ó ULN, the 
patient will undergo repeat confirmatory assessment as soon as is reasonably possible, preferably within 3  to 7 days of the laboratory result becoming available.  
Repeat CK assessment will include query for related symptoms.  
‚Ä¢ If the repeat CK assessment confirms an unexplained (ie, not associated with recent 
trauma or physically strenuous activity) CK abnormality >5 √ó ULN, if asy mptomatic , 
the patient should receive further assessment and investigation into the cause, assess 
whether there is renal injury, and measure CK approximately weekly or more 
frequently if clinically indicated until resolution.  If CK levels continue to rise ; IMP 
should be discontinued the investigator with input from the Sponsor may consider 
continuing study medication with continued CK assessments every 1-2 weeks .  
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 105 of 114 CHANGE 18  ADVERSE EVENT MONITORING REVISION 
Location: 
Section 12.1.3, Reporting for Adverse Events 
Original Text:  
Clinically significant abnormal laboratory or other examination findings that are detected during 
the study or are present at baseline and significantly worsen during the study should be reported 
as AEs.  The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically significant.  
Significant abnormal laboratory values occurring during the clinical study will be followed until 
repeat tests return to normal, stabilize, or are no longer clinically significant.  Any abnormal test 
that is determined to be an error does not require reporting as an AE. 
New  Text:  
Clinically significant abnormal laboratory or other examination findings that are detected during 
the study or are present at baseline and significantly worsen during the study should be reported 
as AEs , as described below .  The investigator will exercise his or her medical and scientific 
judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is 
clinically significant.  Significant abnormal laboratory values occurring during the clinical study 
will be followed until repeat tests return to normal, stabilize, or are no longer clinically significant.  Any abnormal test that is determined to be an error does not require reporting as an 
AE. 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an AE only if any one of the following criteria is met:  
‚Ä¢ an action on the study drug is made as a result of the abnormality 
‚Ä¢ intervention for management of the abnormality is required 
‚Ä¢ at the discretion of the investigator should the abnormality be deemed clinically 
significant  
Location: 
Section 12.6.1, Monitoring and Follow-up of Adverse Events  
Original Text:  
Patients with AEs related to IMP that are ongoing at study discontinuation or completion must be 
followed until resolution or for [ADDRESS_344741], with the 
exception of patients reporting SA Es (see  Section  12.2.2).  
New Text:  
Patients with AEs related to IMP that are  ongoing at study discontinuation or completion mu st be 
followed until resolution, until deemed stable/chronic,  or for [ADDRESS_344742], with the exception of patients reporting SAEs (see Section  12.2.2).  
 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 106 of 114 CHANGE 1 9 SERIOUS ADVERSE EVENT DEFINITION ADDITION 
Location: 
Section 12.2.1., Definition of Serious Adverse Event 
Original Text:  
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical interve ntion to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias, 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
New  Text:  
Important medical events that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they 
may jeopard ize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias, 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
Events or Outcomes Not Qualifying as Serious Adverse Events  
The following are not considered SAEs and therefore do not need to be reported as such:  
‚Ä¢ Preplanned or elective hospi[INVESTIGATOR_171298]/or convenience 
situations (eg, due to inclement weather)  
‚Ä¢ Overdose of either Esperion study drug or concomitant medication unless the event meets SAE criteria (eg, hospi[INVESTIGATOR_059]).  However,  the event should still be 
captured as a nonserious AE on the appropriate eCRF page 
Location: 
Section 12.2.2, Reporting Serious Adverse Events 
Original Text:  
To report the SAE, the SAE form in EDC should be completed within [ADDRESS_344743] update the SAE form and submit any supporting documentation (eg, patient discharge summary or autopsy reports) to designated Safety contact.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 107 of 114 New text:  
To report the SAE, the SAE form in EDC should be completed information should be entered on 
to the AE eCRF in the EDC database within [ADDRESS_344744] update the SAE form  
information on the AE eCRF and submit any supporting documentation (eg, patient discharge 
summary or  autopsy reports) to designated Safety contact.  
Location: 
Section 12.2.3, Reporting of Patient Death 
Original Text:  
The death of any patient during the study or within [ADDRESS_344745] be reported as an SAE. New Text:  
The death of any patient during the study or within [ADDRESS_344746] be reported as an SAE. 
 CHANGE 20  PREGNANCY REPORTING REVISION 
Location: 
Section  12.2.4, Reports of Pregnancy and Lactation 
Original Text : 
Although not considered an SAE (unless an event occurs with a serious outcome), pregnancy 
will be collected by [CONTACT_282647] .  If a female patient should become pregnant 
during the course of the study, the Principal Investigator [INVESTIGATOR_282618] [ADDRESS_344747].  Patients who lactate during the study may be required to discontinue study medication. 
New  Text:  
Although not considered an SAE (unless an event occurs with a serious outcome), any event of 
pregnancy will be collected by [CONTACT_282647] .  If a female patient should become 
pregnant during the course of the study or within [ADDRESS_344748].  Patients who are breastfeeding are excluded from this lactate during the  study may be 
required to and should discontinue study medication.  
 
CHANGE 21  STATISTIC REVISION 
Location: 
Section 13.9, PCSK91 
Original Text:  
13.9 PCSK91  
PCSK9 c oncentrations will be collected and summarized from patients at S1, S2, T1, T2, and T3. 
New Text:  
13.9 PCSK91  
PCSK9 concentrations will be collected and summarized from patients at S1, S2, T1, T2, and T3. 
 
CHANGE 22  CASE REPORT FORMS AND STUDY RECORDS REVISION  
Location: 
Section 17.3, Case Report Forms and Study Recrods 
Original Text:  
It is essential that all dates appearing on the Sponsor‚Äôs patient data collection forms for 
laboratory tests, cultures, etc, be the dates on which the specimens were obtained or the 
procedures performed.  The eCRFs will be electronically signed by [CONTACT_282681].  All data collection forms should be completed 
within 48 hours following the evaluation. 
New Text:  
It is essential that all dates appearing on the Sponsor‚Äôs patient data collection fo rms for 
laboratory tests, cultures, etc, be the dates on which the specimens were obtained or the 
procedures performed.  The eCRFs will be electronically signed by [CONTACT_76788].  All data collection forms should be completed within 48 hours a timely manner according to the eCRF completion guidelines following the 
evaluation. 
 
CHANGE 2 3 SCHEDULE OF EVENTS REVISION  
Location: 
Appendix 1, Schedule of Events 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 109 of 114 Original Text:  
Schedule of Events  
Visit  S11,2 S2 S3 T1 T2 T3/EOS)3 
Week  Month  
-2.5 Month  
-1 Pre- 
randomization  Week  
0 Month  
1 Month  
2 
Day 
Procedure  Day 
-75 Day 
-30¬±[ADDRESS_344749]-S2 Day 
1* Day 
31¬±3 Day 
61¬±3 
Informed Consent X      
Enrollment Criteria X X     
Demographics  X      
Medical History  X      
Concomitant Medications  X X X X X X 
Adverse Event Recording   X X X X X 
Physical Exam  X    X 
Weight4 X   X  X 
Height  X      
Vital Signs6 X X  X X X 
Serology7 X      
Serum Pregnancy/FSH8  X      
Urine pregnancy test for 
women  of childbearing 
potential only     X   
TSH  X      
Clinical Safety Labs9 X   X X X 
Basic Fasting Lipi[INVESTIGATOR_805]10 X X** X*** X X X 
ApoB and hs- CRP   X  X  X 
HbA 1C X   X  X 
PCSK9  X X  X X X 
PK ‚Äì predose trough    X X X 
Diet and exercise counseling
11 X X  X X X 
Establish Patient Eligibility     X   
Randomization    X   
IWRS Contact12 X   X X X 
PCSK9i administered at site  X  X X  
Double-blind Drug 
Dispensing     X X  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 110 of 114 Schedule of Events  
Visit  S11,2 S2 S3 T1 T2 T3/EOS)3 
Week  Month  
-2.5 Month  
-1 Pre- 
randomization  Week  
0 Month  
1 Month  
2 
Day 
Procedure  Day 
-75 Day 
-30¬±[ADDRESS_344750]-S2 Day 
1* Day 
31¬±3 Day 
61¬±3 
IMP Return/Compliance     X X 
PCSK9i 
Return/Accountability  X  X X  
NOTE: For patients who withdraw from study drug treatment, but consent to be followed for safety assessments and return to 
clinic for these visit, the visits will occur according to the protocol schedule.  Safety assessments should include clinical  safety 
and basic lipid lab oratories, adverse events (AEs), physical examination (PE), vital signs, and electrocardiograms (ECGs).  For 
patients who withdraw from study drug treatment, but consent to be followed for safety assessments by [CONTACT_648], the telephone 
contacts will occur acco rding the protocol schedule with information regarding current health status and to collect information 
on AEs (eg, recent procedures, hospi[INVESTIGATOR_602], and if the patient has died, the cause of death).  If a patient does not pro vide 
consent to be followed for safety assessments per the protocol (either by [CONTACT_282673]), Visit  T4 will be 
considered the End of Study (EOS)/Early Withdrawal from study and no further visits will be scheduled.  
[ADDRESS_344751] prior to the next witnessed PCSK9i dose if 
patient fails to meet lipid entry criterion at Visit S1.  If this optional basic fastin g lipid is completed, the average of the 2 lipid 
value s will be used to determine eligibility.  
2 A recheck of blood pressure may be completed prior to T1 if the patient‚Äôs diastolic blood pressure ( DBP ) and/or systolic blood 
pressure ( SBP) meet the exclusion criteria levels.  Patients may randomize after blood pressure medications have been 
adjust ed, the patients have been on stable doses of blood pressure medications for at least 2 weeks, and the repeat blood 
pressure values (DBP and/or SBP) do not meet exclusionary values.  Repeat labs may be completed prior to T1 to determine eligibility if the patient‚Äôs estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) or other labs meet exclusion criteria levels.  If this optional lab is completed, the repeated value w ill 
be used to determine eligibility.  
3 All procedures will be completed for all patients at either EOS if completing the study or early withdrawal.  
4 Body weight will be measured in the morning while fasting, using consistent scales, after voiding, and without shoes and 
outerwear (eg, coats).   
6 Vital signs will include DBP, SBP, heart rate (HR) and will be collected prior to any blood sample collection.  Patient will rest 
for [ADDRESS_344752] completed in women of child -bearing age only. FSH in naturally postmenopausal women ‚â•1 year without 
menses and <55 years;  
9 Clinical safety labs include hematology, blood chemistry, and urinalysis at all visits.  Please refer to laboratory manual fo r 
detailed schedule of tests.  
10 Basic fasting lipi[INVESTIGATOR_282616] (TC), calculated low -density lipoprotein cholesterol (LDL -C),
 non-HDL -C,), and ).   
11 Diet and exercise counseling per local and/or regional guidelines for the management of hyperlipi[INVESTIGATOR_035].  
12 Interactive web response system (IWRS) contact [CONTACT_282674] n 
visit date.  
* Patients must be on PCSK9 for at least 30 days before initiating Day  1.  Day 1 should occur immediately (ideally within 
3 days) after S3, once LDL -C eligibility is established  
** LDL-C must be ‚â•160 mg/dL  and TG <500 mg/d L before initiating PCSK9i.  A local lab may be used to assess LDL -C and 
TG.  
*** LDL-C must be ‚â•70 mg/dL t o qualify for randomization.  A local lab may be used to assess entry LDL -C. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 111 of 114 New Text:  
 Schedule of Events  
Visit  S11,2 S2 S3 S3 T1 T2 T3/EOS)3 
Week  Month  Month -24.5 Month -13  Pre-
randomization  
Month -2 Month -1 Week  0 Month 1 Month 2 
Day 
Procedure  Day -7135 Day-390 ¬±3 Day 1*-60 ¬±3 Day 31-30 ¬±3 Day 
61¬±31* Day31 ¬±3  Day61 ¬±3  
Informed Consent X       
Enrollment Criteria X X X X    
Demographics  X       
Medical History  X       
Concomitant Medications  X X X X X X X 
Adverse Event Recording   X X X X X X 
Physical Exam  X    X X 
Weight4 X    X X X 
Height  X       
Vital Signs6 X X X X X X X 
Serology7 X       
Serum Pregnancy/FSH8  X       
Urine pregnancy test for 
women of childbearing potential only      X   
TSH  X       
Clinical Safety Labs9 X    X X X 
Basic Fasting Lipi[INVESTIGATOR_805]10 X X** X*** X*** X X X 
ApoB and hs- CRP   X   X X X 
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 112 of 114  Schedule of Events  
Visit  S11,2 S2 S3 S3 T1 T2 T3/EOS)3 
Week  Month  Month -24.5 Month -13  Pre-
randomization  
Month -2 Month -1 Week  0 Month 1 Month 2 
Day 
Procedure  Day -7135 Day-390 ¬±3 Day 1*-60 ¬±3 Day 31-30 ¬±3 Day 
61¬±31* Day31 ¬±3  Day61 ¬±3  
HbA 1C X    X  X 
PCSK9  X X X  X X X 
PK ‚Äì predose trough      X X X 
Diet and exercise counseling11 X X   X X X 
Establish Patient Eligibility      X   
Randomization     X   
IWRS Contact12 X    X X X 
PCSK9i administered at site   X X X X X  
Double-blind Drug Dispensing     X X  
IMP Return/Compliance      X X 
PCSK9i Return/Accountability   X X X X X  
NOTE: For patients who withdraw from study drug treatment, but consent to be followed for safety assessments and return to cl inic for these visit, the visits will occur according 
to the protocol schedule.  Safety assessments should include clinical safety and basic lipid laboratories, adverse events (AEs), physical examination (PE), and vital signs , and 
electrocardiograms (ECGs) .  For patients who withdraw from study drug treatment, but consent to be followed for safety assessments by [CONTACT_648], the telep hone contacts will occur 
according the protocol schedule with information regarding current health status and to collect information on AEs (eg, recent procedures, hospi[INVESTIGATOR_602], and if the patient has 
died, the cause of death).  If a patient does not provide consent to be followed for safety assessments per the protocol (either by [CONTACT_282673]), Visit  T4 will be 
considered the End of Study (EOS)/Early Withdrawal from study and no further visits will be scheduled.  
[ADDRESS_344753] prior to the next witnessed PCSK9i dose if patient fails to meet  lipid entry criterion at 
Visit S1.  If this optional basic fasting lipid is completed, the average of the 2  lipid value s will be used to determine eligibility.  
2 A recheck of blood pressure may be completed prior to T1 if the patient‚Äôs diastolic blood pressure ( DBP ) and/or systolic blood pressure ( SBP) meet the exclusion criteria levels.  
Patients may randomize after blood pressure medications have been adjusted, the patients have been on stable doses of blood pressure medications for at least 2 weeks, and the 
repeat blood pressure values (DBP and/or SBP) do not meet exclusionary values.  Repeat labs may be completed prior to T1 to determine eligibility if the patient‚Äôs estimated 
glomerular filtration rate (eGFR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) or other labs meet exclus ion criteria levels.  If this optional lab is 
completed, the repeated value will be used to determine eligibility.  
3 All procedures will be completed for all patients at either T3/EOS if completing the study or early withdrawal.  
Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 113 of 114 4 Body weight will be measured in the morning  while fasting, using consistent scales, after voiding, and without shoes and outerwear (eg, coats).   
6 Vital signs will include DBP, SBP, heart rate (HR) and will be collected prior to any blood sample collection.  Patient will rest for [ADDRESS_344754]  completed in women of child- bearing age only. FSH in naturally postmenopausal women ‚â•1 year without menses and <55 years;  
9 Clinical safety labs include hematology, blood chemistry, and urinalysis at all visits.  Please refer to laboratory manual fo r detailed schedule of tests.  
10 Basic fasting lipi[INVESTIGATOR_282616] (TC), calculated low -density lipoprotein cholesterol (LDL -C), , non -HDL -C,), and 
).   
11 Diet and exercise counseling p er local and/or regional guidelines for the management of hyperlipi[INVESTIGATOR_035].  
12 Interactive web response system (IWRS) contact [CONTACT_282674] n visit date.  
* Patients must be on PCSK9 for at least  30 ¬± 3 days during each month of the PCSK9 run-in period before initiating Day  1.  Day  1 should occur immediately (ideally within 
3 days) after S3, once LDL -C eligibility is established  
** LDL-C must be ‚â•160 mg/dL  and TG <500 mg/d L before initiating PCSK9i.  A local lab may be used to assess LDL -C and TG  for eligibility prior to initiating Repatha, but a 
central lab must also be conducted at this visit.   
*** LDL-C must be ‚â•70 mg/dL to qualify for randomization.  A local  Only a central lab may be used to assess entry LDL -C. 

Bempedoic Acid   Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002-039  Amendment 1, 05 March 2017 
Confidential Page 114 of 114 CHANGE 24  SPONSOR‚ÄôS SIGNATURE [CONTACT_282684]: 
Appendix 2, Sponsor‚Äôs Signature 
[CONTACT_282685]:  
Study Title:  A Randomized, Double-Blind, Parallel Group, Multicenter Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid (ETC -1002) 180 mg 
QD when added to PCSK9 -Inhibitor Therapy 
Study Number:  1002-039 
Final Date: [ADDRESS_344755] to critical review and has been approved by [CONTACT_1034].  
The following personnel contributed to writing and/or approving this protocol: 
 
 
Signed:   Date:   
   
New Text:  
Study Title:  A Randomized, Double-Blind, Parallel Group, Multicenter Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid (ETC -1002) 180 mg 
QD when  added to PCSK9-Inhibitor Therapy 
Study Number:  1002-039 
Final Date: [ADDRESS_344756] to critical review and has been approved by [CONTACT_1034].  
The following personnel contributed to writing and/or approving this protocol: 
 
 
Signed:   Date:   
   
 
